data_1p8b_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1p8b _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.568 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t . . . . . 0 C--O 1.234 0.268 0 CA-C-O 120.748 0.309 . . . . 0.0 111.707 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.41 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.582 HG11 HD12 ' A' ' 29' ' ' ILE . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.672 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.672 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.499 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.428 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.498 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.582 HD12 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.551 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.551 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.568 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo . . . . . 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t . . . . . 0 C--O 1.233 0.216 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.623 HG13 HD11 ' A' ' 29' ' ' ILE . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.404 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.527 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.527 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.595 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.595 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.482 HG13 ' CE2' ' A' ' 31' ' ' TYR . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.623 HD11 HG13 ' A' ' 6' ' ' VAL . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.466 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo . . . . . 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t . . . . . 0 C--O 1.237 0.398 0 CA-C-O 120.978 0.418 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.44 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.574 HG12 HD12 ' A' ' 29' ' ' ILE . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.508 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.508 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.626 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.574 HD12 HG12 ' A' ' 6' ' ' VAL . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.626 ' CE2' HG12 ' A' ' 25' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo . . . . . 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.538 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.086 -0.007 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.655 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 0.8 OUTLIER -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.577 HG11 HD11 ' A' ' 29' ' ' ILE . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.407 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.489 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.431 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.496 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.542 HG12 ' CE2' ' A' ' 31' ' ' TYR . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.577 HD11 HG11 ' A' ' 6' ' ' VAL . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.542 ' CE2' HG12 ' A' ' 25' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.655 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.538 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.431 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo . . . . . 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 120.558 0.218 . . . . 0.0 110.8 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.907 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.456 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.456 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.907 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.421 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.422 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.531 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 6' ' ' VAL . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.531 ' CE2' HG12 ' A' ' 25' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.482 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.482 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo . . . . . 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t . . . . . 0 N--CA 1.446 -0.67 0 CA-C-O 120.596 0.236 . . . . 0.0 110.542 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.593 HG11 HD12 ' A' ' 29' ' ' ILE . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.448 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.777 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.513 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.663 HG12 ' CE2' ' A' ' 31' ' ' TYR . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' A' ' 27' ' ' LEU . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.593 HD12 HG11 ' A' ' 6' ' ' VAL . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.435 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.663 ' CE2' HG12 ' A' ' 25' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.41 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.457 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo . . . . . 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.221 0.534 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.575 HG12 HD11 ' A' ' 29' ' ' ILE . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.833 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.658 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.658 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.422 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.833 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.759 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.569 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.469 HG11 ' CE2' ' A' ' 31' ' ' TYR . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.43 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.421 ' HA ' HD21 ' A' ' 27' ' ' LEU . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.575 HD11 HG12 ' A' ' 6' ' ' VAL . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.468 ' O ' HG11 ' A' ' 6' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.759 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo . . . . . 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.518 -0.265 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.612 HG12 HD12 ' A' ' 29' ' ' ILE . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.727 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.435 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.728 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.51 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.728 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.468 HG12 ' HB3' ' A' ' 33' ' ' ARG . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.56 HG11 ' CE2' ' A' ' 31' ' ' TYR . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.612 HD12 HG12 ' A' ' 6' ' ' VAL . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.422 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.56 ' CE2' HG11 ' A' ' 25' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.468 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.51 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo . . . . . 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.576 HG11 HD12 ' A' ' 29' ' ' ILE . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.7 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.475 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.7 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.475 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 31' ' ' TYR . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.576 HD12 HG11 ' A' ' 6' ' ' VAL . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.445 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.46 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo . . . . . 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.276 0.56 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 29' ' ' ILE . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.453 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.453 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.576 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.426 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.453 HG12 ' CE2' ' A' ' 31' ' ' TYR . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.579 HD12 HG13 ' A' ' 6' ' ' VAL . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.417 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CE2' HG12 ' A' ' 25' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.468 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.576 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo . . . . . 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.751 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.73 0.3 . . . . 0.0 111.516 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.462 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CE1' HG13 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.462 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.406 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.497 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.497 HG22 ' N ' ' A' ' 18' ' ' SER . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.497 ' N ' HG22 ' A' ' 17' ' ' THR . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . 0.442 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.579 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 31' ' ' TYR . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.426 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.582 HD11 HG12 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.751 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.579 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo . . . . . 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m . . . . . 0 N--CA 1.456 -0.175 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.581 HG12 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.501 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.42 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.42 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.431 ' HE2' ' HB2' ' A' ' 12' ' ' MET . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.673 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.423 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.649 HG23 HG11 ' A' ' 25' ' ' VAL . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.423 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.649 HG11 HG23 ' A' ' 23' ' ' ILE . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.478 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.478 HG22 ' HA3' ' A' ' 26' ' ' GLY . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.581 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HE2' HG12 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.501 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.417 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.673 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . 0.659 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.138 0.494 . . . . 0.0 111.999 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.565 HG13 HD11 ' A' ' 29' ' ' ILE . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.774 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.632 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.632 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.6 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.532 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.774 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.422 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.475 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 26' ' ' GLY . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.488 HG12 ' CE2' ' A' ' 31' ' ' TYR . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.401 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.565 HD11 HG13 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.659 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 17.4 Cg_exo . . . . . 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.236 0.345 0 CA-C-O 120.73 0.3 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.915 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' SER . . . . . 0.456 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.915 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.61 HG12 ' CE2' ' A' ' 31' ' ' TYR . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.523 HD11 HG12 ' A' ' 6' ' ' VAL . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.453 ' O ' HG11 ' A' ' 6' ' ' VAL . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CE2' HG12 ' A' ' 25' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo . . . . . 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m . . . . . 0 N--CA 1.454 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' MET . . . . . 0.503 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.503 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' PRO . . . . . 0.725 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' CYS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.541 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' CYS . . . . . 0.725 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.531 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' LEU . . . . . 0.457 ' HA ' HD21 ' A' ' 27' ' ' LEU . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.508 HD11 HG12 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.532 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ARG . . . . . 0.497 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASN . . . . . 0.418 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' PRO . . . . . 0.541 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo . . . . . 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.982 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 p -66.48 130.38 43.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.552 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.568 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t -67.33 132.42 47.66 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.707 -179.012 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.41 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.582 HG11 HD12 ' A' ' 29' ' ' ILE . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.672 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.672 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.499 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.499 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.428 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.498 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.582 HD12 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.498 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.551 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.541 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.551 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.568 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo -76.19 32.58 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.449 ' H ' ' C ' ' A' ' 34' ' ' ASN . 4.1 m -135.77 38.55 2.83 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.867 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.932 -179.649 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.006 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.5 m -73.43 110.53 7.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.501 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.536 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t -65.21 128.2 34.83 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.317 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.623 HG13 HD11 ' A' ' 29' ' ' ILE . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.404 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.527 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.527 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.416 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.595 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.476 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.595 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.429 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.482 HG13 ' CE2' ' A' ' 31' ' ' TYR . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.623 HD11 HG13 ' A' ' 6' ' ' VAL . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.406 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.589 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.536 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.476 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.503 ' C ' ' H ' ' A' ' 36' ' ' SER . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo -70.41 30.96 0.2 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.503 ' H ' ' C ' ' A' ' 34' ' ' ASN . 30.5 t -112.83 -52.74 2.76 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.367 0.603 . . . . 0.0 110.098 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 119.097 -0.835 . . . . 0.0 111.782 179.708 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 CA-C-O 120.527 0.203 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.1 t -73.22 114.68 11.68 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.582 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t -74.72 125.18 28.18 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.814 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.44 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.574 HG12 HD12 ' A' ' 29' ' ' ILE . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.716 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.415 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.508 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.508 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.464 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.626 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.574 HD12 HG12 ' A' ' 6' ' ' VAL . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.626 ' CE2' HG12 ' A' ' 25' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.716 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.401 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo -59.14 -32.67 97.63 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 37.1 t -151.06 -41.94 0.12 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.066 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.799 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.375 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -77.58 59.07 1.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 111.469 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.538 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m -64.87 119.6 10.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.008 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.655 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 0.8 OUTLIER -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.577 HG11 HD11 ' A' ' 29' ' ' ILE . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.407 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.407 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.489 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.431 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.496 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.496 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.542 HG12 ' CE2' ' A' ' 31' ' ' TYR . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.577 HD11 HG11 ' A' ' 6' ' ' VAL . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.542 ' CE2' HG12 ' A' ' 25' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.655 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.538 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.431 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo -78.68 17.84 1.07 Allowed 'Trans proline' 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -88.94 -36.56 15.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.343 0.592 . . . . 0.0 110.215 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.593 -1.115 . . . . 0.0 111.805 179.843 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 110.348 -0.242 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.0 t -74.11 81.99 1.77 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.08 0.467 . . . . 0.0 109.931 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.412 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m -67.72 119.69 12.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.8 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.471 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.907 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.456 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.456 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.907 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.421 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.422 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.531 HG12 ' CE2' ' A' ' 31' ' ' TYR . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.435 HD11 HG12 ' A' ' 6' ' ' VAL . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.531 ' CE2' HG12 ' A' ' 25' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.482 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.482 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo -75.65 33.51 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.461 ' H ' ' C ' ' A' ' 34' ' ' ASN . 2.0 p -132.38 38.31 3.47 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.702 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.847 -0.974 . . . . 0.0 111.605 -179.708 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.672 0.272 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.8 m -79.71 89.26 5.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.202 0.525 . . . . 0.0 110.492 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.41 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t -135.24 133.41 38.96 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.542 -179.072 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.593 HG11 HD12 ' A' ' 29' ' ' ILE . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.513 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.448 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.777 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.777 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.513 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.663 HG12 ' CE2' ' A' ' 31' ' ' TYR . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.427 HD23 ' HA ' ' A' ' 27' ' ' LEU . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.593 HD12 HG11 ' A' ' 6' ' ' VAL . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.435 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.663 ' CE2' HG12 ' A' ' 25' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.41 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.508 ' C ' ' H ' ' A' ' 36' ' ' SER . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.457 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo -67.57 23.64 0.12 Allowed 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.508 ' H ' ' C ' ' A' ' 34' ' ' ASN . 12.9 m -91.1 -14.67 30.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.175 0.512 . . . . 0.0 109.985 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.381 -1.233 . . . . 0.0 111.929 -179.959 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.8 m -67.8 73.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.344 0.592 . . . . 0.0 111.047 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m -139.5 65.61 1.43 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.793 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.575 HG12 HD11 ' A' ' 29' ' ' ILE . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.833 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.658 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.658 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.422 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.833 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.466 HG23 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.403 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.759 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.569 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.443 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.469 HG11 ' CE2' ' A' ' 31' ' ' TYR . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.43 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.421 ' HA ' HD21 ' A' ' 27' ' ' LEU . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.575 HD11 HG12 ' A' ' 6' ' ' VAL . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.468 ' O ' HG11 ' A' ' 6' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.493 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.759 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo -81.14 37.8 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.8 m -88.36 -27.05 21.88 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.602 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.809 -0.995 . . . . 0.0 111.852 179.738 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.733 0.301 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.1 m -62.07 124.46 20.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.142 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m -83.08 59.12 4.77 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.612 HG12 HD12 ' A' ' 29' ' ' ILE . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.727 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.435 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.728 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.51 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.728 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.468 HG12 ' HB3' ' A' ' 33' ' ' ARG . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.56 HG11 ' CE2' ' A' ' 31' ' ' TYR . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.441 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.612 HD12 HG12 ' A' ' 6' ' ' VAL . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.422 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.56 ' CE2' HG11 ' A' ' 25' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.468 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.51 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo -65.31 -35.25 41.29 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.1 m -151.85 49.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.077 0.465 . . . . 0.0 110.501 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.81 -0.995 . . . . 0.0 112.628 -179.569 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 120.823 0.344 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -78.88 104.06 9.25 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m -141.95 126.26 17.59 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.275 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.576 HG11 HD12 ' A' ' 29' ' ' ILE . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.7 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.475 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.7 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.475 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.49 HG11 ' CE2' ' A' ' 31' ' ' TYR . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.576 HD12 HG11 ' A' ' 6' ' ' VAL . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.445 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.517 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.46 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -62.26 -36.08 70.24 Favored 'Trans proline' 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.7 p -92.39 -69.61 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.357 0.598 . . . . 0.0 110.596 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.027 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.425 179.798 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.034 0 CA-C-O 120.91 0.386 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 t -158.84 58.36 0.43 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.459 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m -73.62 91.94 1.9 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.227 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.579 HG13 HD12 ' A' ' 29' ' ' ILE . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.453 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.433 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.453 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.474 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.576 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.426 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.453 HG12 ' CE2' ' A' ' 31' ' ' TYR . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.4 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.579 HD12 HG13 ' A' ' 6' ' ' VAL . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.417 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.453 ' CE2' HG12 ' A' ' 25' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.474 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.468 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.576 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo -78.05 -0.33 10.57 Favored 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.8 p -88.61 -37.48 15.6 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.949 0.404 . . . . 0.0 111.854 -179.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.626 -1.097 . . . . 0.0 112.271 -179.667 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.925 0.393 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 p -77.23 57.87 1.52 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.577 0.703 . . . . 0.0 110.679 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.751 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t -69.08 123.11 20.19 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.516 -178.902 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.543 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.462 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.44 ' CE1' HG13 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.462 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.406 ' HE1' ' HB3' ' A' ' 12' ' ' MET . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.497 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.543 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.497 HG22 ' N ' ' A' ' 18' ' ' SER . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.497 ' N ' HG22 ' A' ' 17' ' ' THR . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . 0.442 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.579 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.497 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.449 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.545 HG11 ' CE2' ' A' ' 31' ' ' TYR . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.426 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.44 HG13 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.582 HD11 HG12 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.449 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.593 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.751 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.579 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo -61.99 -12.73 27.46 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.5 m -89.48 13.21 14.35 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.037 0.446 . . . . 0.0 111.148 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 CA-C-O 118.81 -0.994 . . . . 0.0 111.811 -179.784 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.672 0.272 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.9 t -63.05 145.14 56.09 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.108 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m -77.17 68.97 3.39 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.581 HG12 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.501 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.42 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.42 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.431 ' HE2' ' HB2' ' A' ' 12' ' ' MET . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . . . . . . . . . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.4 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.673 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.423 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.649 HG23 HG11 ' A' ' 25' ' ' VAL . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.423 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.649 HG11 HG23 ' A' ' 23' ' ' ILE . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.478 ' HA3' HG22 ' A' ' 29' ' ' ILE . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.478 HG22 ' HA3' ' A' ' 26' ' ' GLY . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.581 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HE2' HG12 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.501 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.416 ' HD3' ' O ' ' A' ' 37' ' ' GLY . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 36' ' ' SER . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.673 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo -68.16 30.29 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.521 ' H ' ' C ' ' A' ' 34' ' ' ASN . 10.7 t -131.95 34.03 3.88 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.176 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.416 ' O ' ' HD3' ' A' ' 33' ' ' ARG . . . . . . . . 0 C--O 1.252 1.233 0 CA-C-O 118.862 -0.966 . . . . 0.0 111.578 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 m 55.37 45.36 25.57 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.543 0.687 . . . . 0.0 109.962 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.659 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t -65.88 131.91 47.39 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.999 -178.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . 0.483 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.565 HG13 HD11 ' A' ' 29' ' ' ILE . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.774 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.632 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.632 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.6 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.532 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.774 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' THR . . . . . 0.436 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.436 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.422 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.475 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 26' ' ' GLY . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.488 HG12 ' CE2' ' A' ' 31' ' ' TYR . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.401 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.565 HD11 HG13 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.448 ' O ' HG12 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.531 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.659 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.422 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 17.4 Cg_exo -68.31 1.98 3.13 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.7 m -88.82 -49.29 6.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.125 0.488 . . . . 0.0 111.008 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.741 -1.033 . . . . 0.0 111.954 179.629 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.492 ' HB1' ' SG ' ' A' ' 3' ' ' CYS . . . . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.733 0.301 . . . . 0.0 110.59 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.0 m -79.85 57.36 2.55 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.169 0.509 . . . . 0.0 111.266 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . 0.492 ' SG ' ' HB1' ' A' ' 1' ' ' ALA . 60.5 m -83.19 130.19 35.07 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.243 -179.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.915 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' SER . . . . . 0.456 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.915 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.61 HG12 ' CE2' ' A' ' 31' ' ' TYR . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.523 HD11 HG12 ' A' ' 6' ' ' VAL . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.453 ' O ' HG11 ' A' ' 6' ' ' VAL . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.61 ' CE2' HG12 ' A' ' 25' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.68 -0.61 2.07 Favored 'Trans proline' 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.8 t -88.56 -36.85 16.13 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.347 0.594 . . . . 0.0 109.916 179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.968 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.295 179.754 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.69 0.281 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -74.96 67.0 1.63 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.155 0.502 . . . . 0.0 110.7 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m -65.63 120.45 12.96 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.866 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' MET . . . . . 0.503 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.503 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' PRO . . . . . 0.725 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.532 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.541 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' CYS . . . . . 0.725 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.531 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.509 HG13 HG23 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' LEU . . . . . 0.457 ' HA ' HD21 ' A' ' 27' ' ' LEU . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.508 HD11 HG12 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.531 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.532 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ARG . . . . . 0.497 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASN . . . . . 0.418 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' PRO . . . . . 0.541 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo -73.23 41.9 0.61 Allowed 'Trans proline' 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 23.6 p -150.79 27.72 0.71 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.771 0 CA-C-O 118.513 -1.16 . . . . 0.0 112.215 179.933 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t . . . . . 0 C--O 1.234 0.268 0 CA-C-O 120.748 0.309 . . . . 0.0 111.707 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.684 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.684 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.477 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.506 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.431 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.544 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.544 HG13 HG22 ' A' ' 23' ' ' ILE . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.518 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.552 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.552 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.596 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo . . . . . 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t . . . . . 0 C--O 1.233 0.216 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.534 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.534 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.477 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.614 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.557 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.614 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.558 HG22 HG13 ' A' ' 25' ' ' VAL . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.558 HG13 HG22 ' A' ' 23' ' ' ILE . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.557 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo . . . . . 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t . . . . . 0 C--O 1.237 0.398 0 CA-C-O 120.978 0.418 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.725 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.462 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.538 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.538 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.548 HG22 HG13 ' A' ' 25' ' ' VAL . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.548 HG13 HG22 ' A' ' 23' ' ' ILE . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.436 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.436 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.725 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo . . . . . 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.086 -0.007 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.659 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 43.8 t30 -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.507 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.44 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.507 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.496 HG22 ' HA2' ' A' ' 30' ' ' GLY . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.496 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.659 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.561 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.44 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo . . . . . 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.426 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 120.558 0.218 . . . . 0.0 110.8 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.47 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.415 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.463 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.921 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.43 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.575 HG22 HG13 ' A' ' 25' ' ' VAL . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.575 HG13 HG22 ' A' ' 23' ' ' ILE . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.415 HG12 ' CE1' ' A' ' 10' ' ' PHE . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.4 HG12 ' N ' ' A' ' 30' ' ' GLY . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.481 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.481 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo . . . . . 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.426 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t . . . . . 0 N--CA 1.446 -0.67 0 CA-C-O 120.596 0.236 . . . . 0.0 110.542 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.514 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.51 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.817 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.817 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.583 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.514 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.583 HG13 HG22 ' A' ' 23' ' ' ILE . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.51 HG12 ' CE1' ' A' ' 10' ' ' PHE . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.418 HG12 ' N ' ' A' ' 30' ' ' GLY . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.439 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.426 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo . . . . . 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.221 0.534 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.836 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.668 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.668 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.836 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.435 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.789 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.576 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.546 HG22 ' HA2' ' A' ' 30' ' ' GLY . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.546 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.789 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo . . . . . 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.518 -0.265 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.408 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.432 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.741 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.4 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.762 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.762 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 25' ' ' VAL . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 23' ' ' ILE . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.444 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.444 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo . . . . . 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.445 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.487 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.714 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' PRO . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.539 HG22 HG13 ' A' ' 25' ' ' VAL . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 HG22 ' A' ' 23' ' ' ILE . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.459 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo . . . . . 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.276 0.56 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.452 ' SG ' ' N ' ' A' ' 8' ' ' SER . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.417 ' CE1' HG12 ' A' ' 28' ' ' VAL . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.499 HG22 HG13 ' A' ' 25' ' ' VAL . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.499 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo . . . . . 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.758 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.73 0.3 . . . . 0.0 111.516 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.472 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.524 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.472 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.487 HG22 ' HB2' ' A' ' 15' ' ' CYS . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ALA . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.533 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.464 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.499 HG22 ' HA2' ' A' ' 30' ' ' GLY . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.524 HG12 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.448 HD11 HG11 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.499 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo . . . . . 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m . . . . . 0 N--CA 1.456 -0.175 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.494 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.429 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.429 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.675 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.413 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.428 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 30' ' ' GLY . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.466 ' HE2' HG11 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.423 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.675 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' CYS . . . . . 0.677 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.138 0.494 . . . . 0.0 111.999 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.643 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.643 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.621 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.531 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.776 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.483 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.481 HG22 HG13 ' A' ' 25' ' ' VAL . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.481 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.423 HD11 HG11 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.677 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.522 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 17.4 Cg_exo . . . . . 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.236 0.345 0 CA-C-O 120.73 0.3 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.958 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' SER . . . . . 0.472 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.446 ' CE1' HG12 ' A' ' 28' ' ' VAL . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.412 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.958 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.449 HG22 HG13 ' A' ' 25' ' ' VAL . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.449 HG13 HG22 ' A' ' 23' ' ' ILE . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo . . . . . 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m . . . . . 0 N--CA 1.454 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.4 p-10 -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' MET . . . . . 0.506 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.506 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' PRO . . . . . 0.773 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' CYS . . . . . 0.538 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.562 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' CYS . . . . . 0.773 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.547 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.547 HG13 HG22 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.439 HD11 HG11 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' PRO . . . . . 0.562 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo . . . . . 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.982 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 p -66.48 130.38 43.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.552 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t -67.33 132.42 47.66 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.707 -179.012 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.684 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.684 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.477 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.506 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.431 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.544 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.544 HG13 HG22 ' A' ' 23' ' ' ILE . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.518 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.552 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.552 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.596 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo -76.19 32.58 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.413 ' H ' ' C ' ' A' ' 34' ' ' ASN . 4.1 m -135.77 38.55 2.83 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.867 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.932 -179.649 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.006 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.5 m -73.43 110.53 7.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.501 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t -65.21 128.2 34.83 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.317 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.534 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.534 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.477 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.614 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.557 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.614 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.558 HG22 HG13 ' A' ' 25' ' ' VAL . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.558 HG13 HG22 ' A' ' 23' ' ' ILE . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.557 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo -70.41 30.96 0.2 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 34' ' ' ASN . 30.5 t -112.83 -52.74 2.76 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.367 0.603 . . . . 0.0 110.098 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 119.097 -0.835 . . . . 0.0 111.782 179.708 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 CA-C-O 120.527 0.203 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.1 t -73.22 114.68 11.68 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t -74.72 125.18 28.18 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.814 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.725 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.462 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.538 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.538 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.548 HG22 HG13 ' A' ' 25' ' ' VAL . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.548 HG13 HG22 ' A' ' 23' ' ' ILE . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.436 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.436 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.725 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo -59.14 -32.67 97.63 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 37.1 t -151.06 -41.94 0.12 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.066 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.799 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.375 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -77.58 59.07 1.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 111.469 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m -64.87 119.6 10.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.008 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.659 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 43.8 t30 -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.507 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.44 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.507 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.496 HG22 ' HA2' ' A' ' 30' ' ' GLY . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.496 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.659 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.561 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.44 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo -78.68 17.84 1.07 Allowed 'Trans proline' 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -88.94 -36.56 15.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.343 0.592 . . . . 0.0 110.215 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.593 -1.115 . . . . 0.0 111.805 179.843 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 110.348 -0.242 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.0 t -74.11 81.99 1.77 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.08 0.467 . . . . 0.0 109.931 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.426 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m -67.72 119.69 12.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.8 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.47 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.415 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.463 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.921 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.43 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.575 HG22 HG13 ' A' ' 25' ' ' VAL . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.575 HG13 HG22 ' A' ' 23' ' ' ILE . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.415 HG12 ' CE1' ' A' ' 10' ' ' PHE . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.4 HG12 ' N ' ' A' ' 30' ' ' GLY . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.481 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.481 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo -75.65 33.51 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.424 ' H ' ' C ' ' A' ' 34' ' ' ASN . 2.0 p -132.38 38.31 3.47 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.702 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.847 -0.974 . . . . 0.0 111.605 -179.708 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.672 0.272 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.8 m -79.71 89.26 5.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.202 0.525 . . . . 0.0 110.492 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.426 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t -135.24 133.41 38.96 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.542 -179.072 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.514 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.51 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.817 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.817 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.583 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.514 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.583 HG13 HG22 ' A' ' 23' ' ' ILE . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.51 HG12 ' CE1' ' A' ' 10' ' ' PHE . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.418 HG12 ' N ' ' A' ' 30' ' ' GLY . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.439 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.426 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo -67.57 23.64 0.12 Allowed 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.468 ' H ' ' C ' ' A' ' 34' ' ' ASN . 12.9 m -91.1 -14.67 30.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.175 0.512 . . . . 0.0 109.985 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.381 -1.233 . . . . 0.0 111.929 -179.959 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.8 m -67.8 73.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.344 0.592 . . . . 0.0 111.047 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m -139.5 65.61 1.43 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.793 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.836 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.668 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.668 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.836 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.435 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.789 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.576 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.546 HG22 ' HA2' ' A' ' 30' ' ' GLY . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.546 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.789 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo -81.14 37.8 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.8 m -88.36 -27.05 21.88 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.602 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.809 -0.995 . . . . 0.0 111.852 179.738 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.733 0.301 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.1 m -62.07 124.46 20.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.142 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m -83.08 59.12 4.77 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.408 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.432 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.741 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.4 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.762 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.762 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 25' ' ' VAL . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 23' ' ' ILE . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.444 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.444 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo -65.31 -35.25 41.29 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.1 m -151.85 49.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.077 0.465 . . . . 0.0 110.501 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.81 -0.995 . . . . 0.0 112.628 -179.569 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 120.823 0.344 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -78.88 104.06 9.25 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m -141.95 126.26 17.59 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.275 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.445 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.487 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.714 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' PRO . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.539 HG22 HG13 ' A' ' 25' ' ' VAL . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 HG22 ' A' ' 23' ' ' ILE . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.459 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -62.26 -36.08 70.24 Favored 'Trans proline' 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.7 p -92.39 -69.61 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.357 0.598 . . . . 0.0 110.596 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.027 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.425 179.798 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.034 0 CA-C-O 120.91 0.386 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 t -158.84 58.36 0.43 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m -73.62 91.94 1.9 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.227 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.452 ' SG ' ' N ' ' A' ' 8' ' ' SER . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.417 ' CE1' HG12 ' A' ' 28' ' ' VAL . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.499 HG22 HG13 ' A' ' 25' ' ' VAL . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.499 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo -78.05 -0.33 10.57 Favored 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.8 p -88.61 -37.48 15.6 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.949 0.404 . . . . 0.0 111.854 -179.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.626 -1.097 . . . . 0.0 112.271 -179.667 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.925 0.393 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 p -77.23 57.87 1.52 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.577 0.703 . . . . 0.0 110.679 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.758 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t -69.08 123.11 20.19 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.516 -178.902 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.472 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.524 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.472 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.487 HG22 ' HB2' ' A' ' 15' ' ' CYS . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ALA . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.533 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.464 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.499 HG22 ' HA2' ' A' ' 30' ' ' GLY . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.524 HG12 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.448 HD11 HG11 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.499 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo -61.99 -12.73 27.46 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.5 m -89.48 13.21 14.35 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.037 0.446 . . . . 0.0 111.148 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 CA-C-O 118.81 -0.994 . . . . 0.0 111.811 -179.784 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.672 0.272 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.9 t -63.05 145.14 56.09 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.108 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m -77.17 68.97 3.39 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.494 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.429 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.429 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.675 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.413 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.428 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 30' ' ' GLY . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.466 ' HE2' HG11 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.432 ' HD3' ' O ' ' A' ' 37' ' ' GLY . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.494 ' C ' ' H ' ' A' ' 36' ' ' SER . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.675 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo -68.16 30.29 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.494 ' H ' ' C ' ' A' ' 34' ' ' ASN . 10.7 t -131.95 34.03 3.88 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.176 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 33' ' ' ARG . . . . . . . . 0 C--O 1.252 1.233 0 CA-C-O 118.862 -0.966 . . . . 0.0 111.578 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 m 55.37 45.36 25.57 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.543 0.687 . . . . 0.0 109.962 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' CYS . . . . . 0.677 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t -65.88 131.91 47.39 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.999 -178.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.643 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.643 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.621 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.531 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.776 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.483 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.481 HG22 HG13 ' A' ' 25' ' ' VAL . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.481 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.423 HD11 HG11 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.677 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.522 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 17.4 Cg_exo -68.31 1.98 3.13 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.7 m -88.82 -49.29 6.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.125 0.488 . . . . 0.0 111.008 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.741 -1.033 . . . . 0.0 111.954 179.629 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.733 0.301 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.0 m -79.85 57.36 2.55 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.169 0.509 . . . . 0.0 111.266 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 60.5 m -83.19 130.19 35.07 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.243 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.958 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' SER . . . . . 0.472 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.446 ' CE1' HG12 ' A' ' 28' ' ' VAL . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.412 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.958 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.449 HG22 HG13 ' A' ' 25' ' ' VAL . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.449 HG13 HG22 ' A' ' 23' ' ' ILE . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.68 -0.61 2.07 Favored 'Trans proline' 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.8 t -88.56 -36.85 16.13 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.347 0.594 . . . . 0.0 109.916 179.365 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.968 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.295 179.754 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.69 0.281 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -74.96 67.0 1.63 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.155 0.502 . . . . 0.0 110.7 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m -65.63 120.45 12.96 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.866 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.4 p-10 -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' MET . . . . . 0.506 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.506 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' PRO . . . . . 0.773 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.538 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.562 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' CYS . . . . . 0.773 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.547 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.547 HG13 HG22 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.439 HD11 HG11 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' PRO . . . . . 0.562 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo -73.23 41.9 0.61 Allowed 'Trans proline' 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 23.6 p -150.79 27.72 0.71 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.771 0 CA-C-O 118.513 -1.16 . . . . 0.0 112.215 179.933 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t . . . . . 0 C--O 1.234 0.268 0 CA-C-O 120.748 0.309 . . . . 0.0 111.707 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.684 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.684 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.477 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.506 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.431 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.544 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.544 HG13 HG22 ' A' ' 23' ' ' ILE . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.518 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.552 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.552 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.596 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo . . . . . 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t . . . . . 0 C--O 1.233 0.216 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.534 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.534 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.477 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.614 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.557 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.614 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.558 HG22 HG13 ' A' ' 25' ' ' VAL . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.558 HG13 HG22 ' A' ' 23' ' ' ILE . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.557 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo . . . . . 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t . . . . . 0 C--O 1.237 0.398 0 CA-C-O 120.978 0.418 . . . . 0.0 111.814 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.725 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.462 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.538 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.538 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.548 HG22 HG13 ' A' ' 25' ' ' VAL . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.548 HG13 HG22 ' A' ' 23' ' ' ILE . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.436 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.436 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.725 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo . . . . . 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m . . . . . 0 C--O 1.236 0.348 0 CA-C-O 120.086 -0.007 . . . . 0.0 111.008 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.659 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 0.8 OUTLIER -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.507 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.44 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.507 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.496 HG22 ' HA2' ' A' ' 30' ' ' GLY . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.496 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.659 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.561 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.44 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo . . . . . 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.426 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m . . . . . 0 N--CA 1.452 -0.358 0 CA-C-O 120.558 0.218 . . . . 0.0 110.8 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.47 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.415 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.463 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.921 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.43 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.575 HG22 HG13 ' A' ' 25' ' ' VAL . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.575 HG13 HG22 ' A' ' 23' ' ' ILE . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.415 HG12 ' CE1' ' A' ' 10' ' ' PHE . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.4 HG12 ' N ' ' A' ' 30' ' ' GLY . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.481 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.481 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo . . . . . 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.426 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t . . . . . 0 N--CA 1.446 -0.67 0 CA-C-O 120.596 0.236 . . . . 0.0 110.542 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.514 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.51 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.817 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.817 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.583 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.514 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.583 HG13 HG22 ' A' ' 23' ' ' ILE . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.51 HG12 ' CE1' ' A' ' 10' ' ' PHE . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.418 HG12 ' N ' ' A' ' 30' ' ' GLY . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.439 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.426 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo . . . . . 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.449 -0.503 0 CA-C-O 121.221 0.534 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.836 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.668 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.668 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.836 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.435 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.789 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.576 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.546 HG22 ' HA2' ' A' ' 30' ' ' GLY . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.546 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.789 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo . . . . . 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m . . . . . 0 CA--C 1.518 -0.265 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.408 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.432 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.741 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.4 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.762 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.762 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 25' ' ' VAL . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 23' ' ' ILE . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.444 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.444 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo . . . . . 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m . . . . . 0 N--CA 1.451 -0.401 0 N-CA-C 110.275 -0.268 . . . . 0.0 110.275 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.445 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.487 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.714 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' PRO . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.539 HG22 HG13 ' A' ' 25' ' ' VAL . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 HG22 ' A' ' 23' ' ' ILE . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.459 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo . . . . . 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m . . . . . 0 N--CA 1.453 -0.315 0 CA-C-O 121.276 0.56 . . . . 0.0 111.227 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.452 ' SG ' ' N ' ' A' ' 8' ' ' SER . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.417 ' CE1' HG12 ' A' ' 28' ' ' VAL . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.499 HG22 HG13 ' A' ' 25' ' ' VAL . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.499 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo . . . . . 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.758 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t . . . . . 0 N--CA 1.454 -0.232 0 CA-C-O 120.73 0.3 . . . . 0.0 111.516 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.472 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.524 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.472 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.487 HG22 ' HB2' ' A' ' 15' ' ' CYS . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.533 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.464 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.499 HG22 ' HA2' ' A' ' 30' ' ' GLY . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.524 HG12 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.448 HD11 HG11 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.499 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo . . . . . 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m . . . . . 0 N--CA 1.456 -0.175 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.494 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.429 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.429 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.675 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.413 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.428 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 30' ' ' GLY . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.466 ' HE2' HG11 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.423 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.675 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo . . . . . 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . 0.677 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 121.138 0.494 . . . . 0.0 111.999 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.643 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.643 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.621 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.531 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.776 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.483 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.481 HG22 HG13 ' A' ' 25' ' ' VAL . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.481 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.423 HD11 HG11 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.677 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.522 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 17.4 Cg_exo . . . . . 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 60.5 m . . . . . 0 C--O 1.236 0.345 0 CA-C-O 120.73 0.3 . . . . 0.0 111.243 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.958 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . 0.472 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.446 ' CE1' HG12 ' A' ' 28' ' ' VAL . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.412 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.958 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.449 HG22 HG13 ' A' ' 25' ' ' VAL . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.449 HG13 HG22 ' A' ' 23' ' ' ILE . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.446 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo . . . . . 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m . . . . . 0 N--CA 1.454 -0.247 0 CA-C-O 120.976 0.417 . . . . 0.0 111.866 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' MET . . . . . 0.506 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.506 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' PRO . . . . . 0.773 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' CYS . . . . . 0.538 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.562 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' CYS . . . . . 0.773 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.547 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.547 HG13 HG22 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.439 HD11 HG11 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' TYR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' PRO . . . . . 0.562 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo . . . . . 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.982 0 N-CA-C 110.302 -0.259 . . . . 0.0 110.302 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.4 p -66.48 130.38 43.01 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.552 179.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.596 ' HB3' ' HB3' ' A' ' 34' ' ' ASN . 43.8 t -67.33 132.42 47.66 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.707 -179.012 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.414 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 37.2 t30 -173.47 134.36 0.51 Allowed 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.307 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -151.06 22.03 Favored Glycine 0 C--O 1.224 -0.491 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.618 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.55 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 40.8 t -120.01 141.14 41.58 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.525 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 6.6 p -150.06 150.32 31.56 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 116.467 -0.333 . . . . 0.0 111.002 -179.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.684 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 19.7 t -83.25 132.73 49.31 Favored Pre-proline 0 N--CA 1.44 -0.975 0 N-CA-C 106.455 -1.683 . . . . 0.0 106.455 176.443 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_exo -62.14 -11.41 21.86 Favored 'Trans proline' 0 C--O 1.231 0.135 0 C-N-CA 122.361 2.041 . . . . 0.0 112.354 -178.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.6 m-85 -89.15 -21.14 23.47 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.47 179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.684 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 57.6 mt-10 -72.48 131.39 42.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 121.105 0.479 . . . . 0.0 111.716 -179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.477 ' SD ' ' HA ' ' A' ' 13' ' ' PRO . 15.7 tpt -143.22 118.66 6.43 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.499 177.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.506 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 89.0 Cg_endo -83.66 143.08 44.05 Favored 'Cis proline' 0 CA--C 1.531 0.357 0 C-N-CA 123.393 -1.503 . . . . 0.0 111.998 -0.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.506 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 9.0 Cg_exo -69.33 140.91 45.49 Favored 'Trans proline' 0 C--O 1.233 0.229 0 C-N-CA 122.918 2.412 . . . . 0.0 111.871 -179.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.3 m 59.21 30.55 20.33 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.76 -179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 56.54 44.48 90.62 Favored Glycine 0 CA--C 1.52 0.359 0 CA-C-N 115.822 -0.626 . . . . 0.0 114.247 178.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.6 t -168.69 134.03 1.68 Allowed 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 121.236 0.541 . . . . 0.0 110.972 179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.5 m -86.71 -7.59 58.16 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.509 -179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.41 -23.36 54.0 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.945 -179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 14.9 t -98.18 176.69 5.64 Favored 'General case' 0 C--N 1.319 -0.725 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.624 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -140.01 144.0 36.74 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.246 -0.65 . . . . 0.0 109.246 178.172 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.431 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 10.9 t -96.02 125.94 40.91 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.398 -177.955 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.544 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -90.41 114.78 62.31 Favored Pre-proline 0 C--N 1.325 -0.47 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.3 Cg_exo -73.63 64.15 4.72 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 123.012 2.474 . . . . 0.0 114.059 -178.27 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.544 HG13 HG22 ' A' ' 23' ' ' ILE . 17.9 m -84.34 44.79 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.488 0 CA-C-O 121.814 0.816 . . . . 0.0 109.735 178.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.6 164.23 30.25 Favored Glycine 0 N--CA 1.44 -1.088 0 N-CA-C 110.444 -1.063 . . . . 0.0 110.444 -178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 93.2 mt -61.48 -48.59 80.39 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-O 120.862 0.363 . . . . 0.0 110.749 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.9 m -133.56 24.33 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.158 0.504 . . . . 0.0 110.804 179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.416 HD11 HG11 ' A' ' 6' ' ' VAL . 16.2 tt -150.14 145.25 17.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.801 179.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.518 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -151.85 -153.52 6.26 Favored Glycine 0 N--CA 1.435 -1.385 0 N-CA-C 110.298 -1.121 . . . . 0.0 110.298 179.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.552 ' HE1' ' HD3' ' A' ' 33' ' ' ARG . 17.8 p90 -139.43 143.59 37.67 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 117.657 0.728 . . . . 0.0 110.912 179.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.541 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 53.3 m -75.69 127.49 33.16 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.386 179.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.552 ' HD3' ' HE1' ' A' ' 31' ' ' TYR . 53.7 ttp180 -140.48 128.94 22.68 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.392 0.615 . . . . 0.0 109.424 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.596 ' HB3' ' HB3' ' A' ' 3' ' ' CYS . 15.8 p30 -75.39 136.25 71.95 Favored Pre-proline 0 C--N 1.317 -0.825 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.764 -179.178 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 2.7 Cg_exo -76.19 32.58 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 123.023 2.482 . . . . 0.0 111.441 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.413 ' H ' ' C ' ' A' ' 34' ' ' ASN . 4.1 m -135.77 38.55 2.83 Favored 'General case' 0 N--CA 1.451 -0.397 0 CA-C-N 115.883 -0.599 . . . . 0.0 109.867 -179.777 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.511 -1.161 . . . . 0.0 111.932 -179.649 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.006 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 9.5 m -73.43 110.53 7.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.475 -0.329 . . . . 0.0 110.501 179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.555 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.6 t -65.21 128.2 34.83 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.317 179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 37.1 t30 -170.31 132.02 1.0 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.02 0.438 . . . . 0.0 110.913 -179.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 158.66 -146.19 12.76 Favored Glycine 0 N--CA 1.449 -0.447 0 N-CA-C 111.665 -0.574 . . . . 0.0 111.665 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.6 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 47.1 t -122.51 140.05 47.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.62 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 179.239 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 6.6 p -138.0 -160.22 1.04 Allowed 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 120.799 0.333 . . . . 0.0 110.622 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.534 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 40.7 t -146.74 138.02 13.02 Favored Pre-proline 0 N--CA 1.447 -0.592 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.876 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 24.9 Cg_exo -64.94 -10.38 25.09 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 123.234 2.622 . . . . 0.0 112.669 -179.483 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 5.2 m-85 -87.7 -20.83 25.71 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.531 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.534 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 96.1 mt-10 -68.49 133.72 49.03 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.15 179.971 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.477 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 53.7 ttm -144.11 104.28 4.79 Favored Pre-proline 0 C--N 1.323 -0.582 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.27 179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.477 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 87.8 Cg_endo -77.6 144.66 77.63 Favored 'Cis proline' 0 C--O 1.233 0.268 0 C-N-CA 123.595 -1.419 . . . . 0.0 111.944 -0.341 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.614 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 19.8 Cg_exo -64.23 144.17 85.71 Favored 'Trans proline' 0 C--O 1.233 0.272 0 C-N-CA 122.8 2.333 . . . . 0.0 113.128 -179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 1.8 t 62.22 26.54 15.92 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.26 179.183 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.14 38.61 86.94 Favored Glycine 0 CA--C 1.518 0.267 0 CA-C-N 115.829 -0.623 . . . . 0.0 114.171 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 13.9 t -169.84 139.61 1.96 Allowed 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 117.356 0.578 . . . . 0.0 111.009 179.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.3 m -87.98 -17.7 30.68 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.25 -179.965 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -70.85 -29.85 66.08 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.839 -0.618 . . . . 0.0 111.38 -179.26 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.557 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 34.3 t -99.49 -178.42 3.89 Favored 'General case' 0 C--N 1.32 -0.695 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.494 ' HG2' ' O ' ' A' ' 33' ' ' ARG . 12.6 ptm180 -140.94 152.14 44.77 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 178.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.614 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.9 t -102.34 126.26 49.3 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.903 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.558 HG22 HG13 ' A' ' 25' ' ' VAL . 31.8 mm -90.78 112.32 52.75 Favored Pre-proline 0 C--N 1.321 -0.634 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.5 Cg_exo -75.25 66.17 6.24 Favored 'Trans proline' 0 C--O 1.234 0.283 0 C-N-CA 123.219 2.613 . . . . 0.0 114.198 -177.642 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.558 HG13 HG22 ' A' ' 23' ' ' ILE . 16.3 m -86.88 39.24 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 109.853 178.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.93 152.53 9.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.728 -178.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.1 mt -54.78 -46.7 74.47 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 112.214 0.449 . . . . 0.0 112.214 -179.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -129.59 22.38 2.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 121.037 0.446 . . . . 0.0 111.048 179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.43 143.04 16.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.631 0 CA-C-O 121.169 0.509 . . . . 0.0 111.431 179.562 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -146.28 -157.99 7.56 Favored Glycine 0 N--CA 1.437 -1.279 0 N-CA-C 110.193 -1.163 . . . . 0.0 110.193 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.6 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 15.6 p90 -140.15 141.36 36.06 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 117.776 0.788 . . . . 0.0 109.997 178.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.555 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 32.3 m -74.14 125.65 28.82 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.115 -178.347 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.494 ' O ' ' HG2' ' A' ' 21' ' ' ARG . 30.3 ttm180 -142.61 137.92 30.37 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.043 -0.526 . . . . 0.0 109.704 178.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.6 p30 -66.81 140.94 96.5 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.277 179.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.557 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 14.5 Cg_exo -70.41 30.96 0.2 Allowed 'Trans proline' 0 CA--C 1.533 0.429 0 C-N-CA 122.995 2.463 . . . . 0.0 112.454 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.458 ' H ' ' C ' ' A' ' 34' ' ' ASN . 30.5 t -112.83 -52.74 2.76 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.367 0.603 . . . . 0.0 110.098 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.984 0 CA-C-O 119.097 -0.835 . . . . 0.0 111.782 179.708 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.035 0 CA-C-O 120.527 0.203 . . . . 0.0 110.467 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 14.1 t -73.22 114.68 11.68 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.594 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 49.5 t -74.72 125.18 28.18 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.814 -178.836 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.439 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 18.7 p30 -168.51 124.12 0.96 Allowed 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.415 -0.812 . . . . 0.0 109.988 178.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 171.7 -150.6 13.55 Favored Glycine 0 CA--C 1.504 -0.599 0 N-CA-C 110.699 -0.961 . . . . 0.0 110.699 -179.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.0 t -111.56 141.71 26.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 117.272 0.536 . . . . 0.0 110.856 179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.725 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 26.5 p -133.6 151.66 51.74 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.507 -179.501 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.403 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 16.9 t -112.59 132.79 22.05 Favored Pre-proline 0 C--N 1.318 -0.771 0 N-CA-C 109.204 -0.665 . . . . 0.0 109.204 178.907 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 23.6 Cg_exo -65.95 -9.73 24.31 Favored 'Trans proline' 0 C--N 1.343 0.272 0 C-N-CA 123.026 2.484 . . . . 0.0 112.257 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -87.35 -34.32 18.87 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.154 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 50.6 mt-10 -85.49 131.21 34.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.443 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 57.5 ttp -142.75 112.63 5.86 Favored Pre-proline 0 C--N 1.325 -0.487 0 N-CA-C 110.096 -0.335 . . . . 0.0 110.096 179.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.462 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 21.3 Cg_exo -65.39 143.33 58.01 Favored 'Cis proline' 0 C--N 1.348 0.552 0 C-N-CA 123.961 -1.266 . . . . 0.0 112.164 -0.389 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.538 ' HG2' ' HB2' ' A' ' 22' ' ' CYS . 32.5 Cg_exo -58.0 -74.04 0.03 OUTLIER 'Trans proline' 0 CA--C 1.53 0.294 0 C-N-CA 122.965 2.443 . . . . 0.0 112.824 -178.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 95.8 m -75.78 -48.0 23.49 Favored 'General case' 0 C--N 1.324 -0.505 0 C-N-CA 121.001 -0.28 . . . . 0.0 111.22 -179.923 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 164.81 -57.54 0.26 Allowed Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.015 -1.088 . . . . 0.0 112.991 179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.8 t -82.42 132.1 35.21 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.128 0.489 . . . . 0.0 110.683 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 2.2 p -70.98 -17.98 62.63 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.266 179.478 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.18 -21.31 66.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.337 179.566 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 10.7 t -97.9 172.43 7.66 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.214 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 11.0 ptp180 -133.71 146.76 51.1 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 116.315 -0.402 . . . . 0.0 110.198 179.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.538 ' HB2' ' HG2' ' A' ' 14' ' ' PRO . 53.5 t -95.37 130.12 42.27 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.842 -0.617 . . . . 0.0 111.203 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.548 HG22 HG13 ' A' ' 25' ' ' VAL . 30.6 mm -101.65 103.96 31.53 Favored Pre-proline 0 C--N 1.322 -0.624 0 N-CA-C 108.049 -1.093 . . . . 0.0 108.049 177.92 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.462 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 12.6 Cg_exo -71.04 67.94 2.46 Favored 'Trans proline' 0 CA--C 1.53 0.275 0 C-N-CA 123.417 2.745 . . . . 0.0 114.46 -177.508 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.548 HG13 HG22 ' A' ' 23' ' ' ILE . 17.2 m -83.77 36.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.506 0.67 . . . . 0.0 110.17 178.059 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.76 158.42 27.45 Favored Glycine 0 N--CA 1.441 -0.991 0 N-CA-C 110.735 -0.946 . . . . 0.0 110.735 -179.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 84.7 mt -61.31 -40.12 93.01 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.683 0.277 . . . . 0.0 111.279 -179.55 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.5 m -133.02 20.7 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.807 0.336 . . . . 0.0 111.307 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.436 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.3 tt -152.01 162.69 2.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 120.996 0.427 . . . . 0.0 110.816 179.599 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.436 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -167.11 -158.18 11.23 Favored Glycine 0 N--CA 1.438 -1.196 0 N-CA-C 110.313 -1.115 . . . . 0.0 110.313 179.545 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.526 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 22.8 p90 -141.14 141.56 34.15 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.55 0.675 . . . . 0.0 110.46 178.972 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.725 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 9.7 m -80.43 136.24 36.31 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-O 121.249 0.547 . . . . 0.0 110.843 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.6 ttm180 -142.75 139.0 30.89 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.432 179.577 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 14.1 p30 -73.9 134.54 78.06 Favored Pre-proline 0 C--N 1.317 -0.822 0 C-N-CA 120.674 -0.411 . . . . 0.0 110.364 179.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 31.4 Cg_exo -59.14 -32.67 97.63 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.484 2.123 . . . . 0.0 110.829 179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 37.1 t -151.06 -41.94 0.12 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.066 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.799 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.375 179.958 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.894 0 N-CA-C 110.342 -0.244 . . . . 0.0 110.342 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 35.4 m -77.58 59.07 1.88 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.934 0.397 . . . . 0.0 111.469 -179.998 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.561 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 56.9 m -64.87 119.6 10.97 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.008 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.659 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 0.8 OUTLIER -173.26 134.32 0.53 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.963 0.411 . . . . 0.0 110.781 178.696 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 153.08 -143.39 10.2 Favored Glycine 0 C--O 1.221 -0.686 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.51 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 66.5 t -115.63 144.63 22.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 23.2 p -148.47 145.82 28.12 Favored 'General case' 0 C--N 1.32 -0.694 0 CA-C-O 120.929 0.395 . . . . 0.0 111.15 -179.275 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.423 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 28.5 t -98.07 131.6 26.2 Favored Pre-proline 0 C--N 1.32 -0.706 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.288 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -67.23 -1.56 6.57 Favored 'Trans proline' 0 C--O 1.234 0.303 0 C-N-CA 123.177 2.585 . . . . 0.0 112.521 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -88.47 -35.62 16.92 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.123 179.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 39.7 mt-10 -73.33 132.88 43.58 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.431 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 67.2 mtt -140.85 124.2 10.07 Favored Pre-proline 0 C--N 1.323 -0.554 0 CA-C-N 116.435 -0.348 . . . . 0.0 110.324 179.543 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.417 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 90.3 Cg_endo -76.15 140.64 67.06 Favored 'Cis proline' 0 C--O 1.236 0.396 0 C-N-CA 123.182 -1.591 . . . . 0.0 112.37 -0.217 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.507 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 39.5 Cg_exo -56.91 149.95 58.08 Favored 'Trans proline' 0 C--N 1.342 0.205 0 C-N-CA 123.153 2.569 . . . . 0.0 112.376 179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 7.6 m 66.04 13.85 9.3 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.904 -179.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.61 30.46 77.7 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 121.233 -0.508 . . . . 0.0 112.442 -179.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 9.9 t -164.96 140.34 5.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.266 0.555 . . . . 0.0 110.931 179.945 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 6.9 m -72.9 -20.94 60.99 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.961 -0.563 . . . . 0.0 111.294 -179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -72.62 -28.82 62.99 Favored 'General case' 0 C--N 1.327 -0.377 0 N-CA-C 113.101 0.778 . . . . 0.0 113.101 -178.706 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.7 m -98.75 140.47 32.89 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.802 0.334 . . . . 0.0 111.765 -178.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.44 ' NE ' ' HB3' ' A' ' 35' ' ' PRO . 8.0 ptp180 -104.16 148.85 25.81 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 109.927 -0.398 . . . . 0.0 109.927 178.66 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.507 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 38.0 t -102.15 131.13 48.84 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.287 -179.268 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 30.0 mm -99.96 102.89 19.15 Favored Pre-proline 0 C--N 1.329 -0.29 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.495 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 10.0 Cg_exo -72.88 68.08 3.89 Favored 'Trans proline' 0 CA--C 1.529 0.238 0 C-N-CA 123.554 2.836 . . . . 0.0 113.968 -178.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.496 HG22 ' HA2' ' A' ' 30' ' ' GLY . 4.3 m -67.91 -38.16 79.58 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 121.074 0.464 . . . . 0.0 110.403 178.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -93.82 -173.31 39.45 Favored Glycine 0 N--CA 1.447 -0.595 0 N-CA-C 110.777 -0.929 . . . . 0.0 110.777 177.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.6 mt -74.67 -54.32 7.64 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 117.035 0.418 . . . . 0.0 110.69 179.513 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 35.5 m -121.09 19.5 5.78 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-O 121.447 0.641 . . . . 0.0 110.449 179.817 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.3 tt -145.46 152.18 14.54 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.414 -0.812 . . . . 0.0 109.959 179.463 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.496 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.68 -159.49 9.58 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 179.765 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.51 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.7 p90 -132.79 139.09 47.36 Favored 'General case' 0 C--N 1.312 -1.026 0 C-N-CA 120.112 -0.635 . . . . 0.0 110.41 178.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.659 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 12.2 t -74.0 134.48 43.07 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.63 -178.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 34.5 ttm180 -141.52 138.96 33.12 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.83 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.561 ' N ' ' HB2' ' A' ' 3' ' ' CYS . 13.6 p30 -78.23 131.59 68.78 Favored Pre-proline 0 C--N 1.319 -0.724 0 CA-C-O 121.137 0.494 . . . . 0.0 110.461 179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.44 ' HB3' ' NE ' ' A' ' 21' ' ' ARG . 63.4 Cg_endo -78.68 17.84 1.07 Allowed 'Trans proline' 0 N--CA 1.46 -0.441 0 C-N-CA 122.575 2.183 . . . . 0.0 111.837 179.848 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.3 m -88.94 -36.56 15.83 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.343 0.592 . . . . 0.0 110.215 179.797 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.108 0 CA-C-O 118.593 -1.115 . . . . 0.0 111.805 179.843 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.937 0 N-CA-C 110.348 -0.242 . . . . 0.0 110.348 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 32.0 t -74.11 81.99 1.77 Allowed 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.08 0.467 . . . . 0.0 109.931 179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.426 ' HB2' ' N ' ' A' ' 34' ' ' ASN . 40.0 m -67.72 119.69 12.86 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 115.772 -0.649 . . . . 0.0 110.8 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.475 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 11.4 t-20 -174.61 126.86 0.31 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.059 179.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 157.78 -150.24 21.07 Favored Glycine 0 C--O 1.222 -0.606 0 N-CA-C 110.579 -1.008 . . . . 0.0 110.579 -179.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 93.2 t -110.65 147.01 15.09 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.797 0 CA-C-N 117.254 0.527 . . . . 0.0 110.096 178.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.921 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 26.0 p -145.01 138.72 26.96 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 -179.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.47 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 26.2 t -102.13 136.23 19.49 Favored Pre-proline 0 C--N 1.32 -0.684 0 C-N-CA 120.798 -0.361 . . . . 0.0 110.256 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.47 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.6 Cg_exo -63.47 -20.47 69.88 Favored 'Trans proline' 0 C--N 1.345 0.36 0 C-N-CA 123.002 2.468 . . . . 0.0 111.638 179.438 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.415 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.8 m-85 -88.56 -38.12 15.16 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.309 -179.948 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.463 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 27.9 mm-40 -69.13 137.25 53.25 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.208 179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 21.4 ttt -142.75 115.75 6.19 Favored Pre-proline 0 C--N 1.321 -0.644 0 N-CA-C 110.411 -0.218 . . . . 0.0 110.411 179.365 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -71.77 135.95 40.21 Favored 'Cis proline' 0 C--N 1.345 0.394 0 C-N-CA 123.678 -1.384 . . . . 0.0 112.207 -0.308 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.921 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 11.0 Cg_endo -56.11 -57.71 1.37 Allowed 'Trans proline' 0 N--CA 1.473 0.308 0 C-N-CA 123.412 2.741 . . . . 0.0 113.034 -179.222 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.7 t -75.55 -28.37 59.01 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.421 -0.808 . . . . 0.0 110.696 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 103.86 32.2 4.51 Favored Glycine 0 N--CA 1.449 -0.443 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 -179.26 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -179.95 139.38 0.13 Allowed 'General case' 0 C--N 1.326 -0.425 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 179.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.6 t -75.31 -21.42 58.46 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 121.041 0.448 . . . . 0.0 109.88 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.51 -24.59 67.17 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.714 -0.675 . . . . 0.0 111.655 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.454 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 75.7 m -113.07 143.51 44.21 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-N 116.299 -0.409 . . . . 0.0 110.389 -179.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.6 ptp180 -102.37 155.97 17.9 Favored 'General case' 0 C--O 1.235 0.3 0 CA-C-O 121.324 0.583 . . . . 0.0 111.312 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.43 ' HB2' ' CG ' ' A' ' 14' ' ' PRO . 42.9 t -97.68 129.15 44.77 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.249 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.575 HG22 HG13 ' A' ' 25' ' ' VAL . 31.2 mm -101.75 106.31 46.11 Favored Pre-proline 0 C--N 1.323 -0.565 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_exo -72.83 67.58 3.9 Favored 'Trans proline' 0 CA--C 1.528 0.175 0 C-N-CA 123.37 2.713 . . . . 0.0 114.403 -177.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.575 HG13 HG22 ' A' ' 23' ' ' ILE . 17.8 m -85.07 38.32 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 121.584 0.707 . . . . 0.0 110.312 178.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -177.12 162.15 30.15 Favored Glycine 0 N--CA 1.443 -0.839 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 97.8 mt -64.4 -46.98 80.94 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 116.958 0.379 . . . . 0.0 111.332 -179.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.415 HG12 ' CE1' ' A' ' 10' ' ' PHE . 34.8 m -126.37 20.08 3.57 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-O 121.026 0.441 . . . . 0.0 110.948 -179.965 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.4 HG12 ' N ' ' A' ' 30' ' ' GLY . 16.4 tt -151.58 155.39 7.06 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 121.173 0.511 . . . . 0.0 110.933 179.401 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.4 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.44 -157.46 8.58 Favored Glycine 0 N--CA 1.438 -1.182 0 N-CA-C 109.622 -1.391 . . . . 0.0 109.622 179.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 14.9 p90 -140.44 144.06 35.92 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 117.907 0.854 . . . . 0.0 111.236 178.8 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.475 ' O ' ' HA ' ' A' ' 4' ' ' ASN . 52.5 t -74.24 126.94 31.72 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.143 -0.935 . . . . 0.0 109.796 179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.481 ' HG2' ' N ' ' A' ' 34' ' ' ASN . 13.5 ttm180 -140.9 151.28 44.14 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.481 ' N ' ' HG2' ' A' ' 33' ' ' ARG . 16.5 p30 -66.72 134.18 94.18 Favored Pre-proline 0 C--N 1.319 -0.736 0 CA-C-N 115.955 -0.566 . . . . 0.0 111.154 -179.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.454 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 59.8 Cg_endo -75.65 33.51 0.4 Allowed 'Trans proline' 0 N--CA 1.462 -0.336 0 C-N-CA 123.141 2.561 . . . . 0.0 111.786 179.709 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.424 ' H ' ' C ' ' A' ' 34' ' ' ASN . 2.0 p -132.38 38.31 3.47 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.702 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.977 0 CA-C-O 118.847 -0.974 . . . . 0.0 111.605 -179.708 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.029 0 CA-C-O 120.672 0.272 . . . . 0.0 110.597 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 43.8 m -79.71 89.26 5.17 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.202 0.525 . . . . 0.0 110.492 179.727 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.426 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 8.8 t -135.24 133.41 38.96 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.542 -179.072 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 15.3 p30 -174.97 152.24 1.47 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.016 -179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.59 -155.99 21.85 Favored Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.469 -0.652 . . . . 0.0 111.469 -179.645 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.556 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.5 t -118.05 143.88 27.6 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.926 0 CA-C-O 120.813 0.34 . . . . 0.0 110.58 179.694 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 4.5 p -140.36 -155.85 0.62 Allowed 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.088 179.801 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.441 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 33.1 t -152.92 141.69 14.23 Favored Pre-proline 0 N--CA 1.449 -0.517 0 CA-C-O 120.646 0.26 . . . . 0.0 110.533 -179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.514 ' HG3' ' HB3' ' A' ' 24' ' ' PRO . 23.5 Cg_exo -66.14 -19.8 56.76 Favored 'Trans proline' 0 C--N 1.344 0.331 0 C-N-CA 123.473 2.782 . . . . 0.0 112.613 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.51 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.6 m-85 -88.43 -35.71 16.92 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.991 -179.116 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -64.83 132.32 49.16 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.649 -179.455 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 16.5 tmm? -141.68 121.2 8.14 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.162 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_exo -72.0 137.54 48.75 Favored 'Cis proline' 0 C--N 1.346 0.428 0 C-N-CA 123.489 -1.463 . . . . 0.0 111.224 -0.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.817 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 36.4 Cg_endo -67.13 135.66 38.07 Favored 'Trans proline' 0 N--CA 1.455 -0.787 0 C-N-CA 121.915 1.743 . . . . 0.0 111.437 -179.852 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 6.3 t 78.32 -39.03 0.25 Allowed 'General case' 0 C--N 1.33 -0.265 0 O-C-N 124.012 0.82 . . . . 0.0 110.416 -178.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 144.87 -57.18 0.53 Allowed Glycine 0 N--CA 1.447 -0.617 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.516 179.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.0 t -95.18 137.4 34.29 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 120.941 0.401 . . . . 0.0 111.097 -179.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 24.7 m -75.23 -15.61 60.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.347 179.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -67.25 -25.26 65.99 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.893 179.672 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.43 ' SG ' ' N ' ' A' ' 21' ' ' ARG . 49.9 t -97.87 -176.04 3.34 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.43 ' N ' ' SG ' ' A' ' 20' ' ' CYS . 10.6 ptm180 -140.19 147.21 39.75 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.06 0.457 . . . . 0.0 109.92 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.817 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 42.3 t -102.09 127.76 48.85 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.465 -179.45 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.583 HG22 HG13 ' A' ' 25' ' ' VAL . 30.3 mm -92.77 110.89 48.41 Favored Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 178.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.514 ' HB3' ' HG3' ' A' ' 9' ' ' PRO . 3.9 Cg_exo -74.46 68.34 5.28 Favored 'Trans proline' 0 C--O 1.234 0.277 0 C-N-CA 123.3 2.667 . . . . 0.0 113.699 -178.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.583 HG13 HG22 ' A' ' 23' ' ' ILE . 16.0 m -84.71 36.29 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-O 121.466 0.65 . . . . 0.0 110.335 178.538 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.24 166.76 38.91 Favored Glycine 0 N--CA 1.442 -0.945 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 92.9 mt -61.86 -51.37 68.47 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.889 0.345 . . . . 0.0 111.319 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.51 HG12 ' CE1' ' A' ' 10' ' ' PHE . 33.4 m -128.18 20.24 2.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.125 0.488 . . . . 0.0 111.054 -179.995 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.418 HG12 ' N ' ' A' ' 30' ' ' GLY . 12.8 tt -142.59 154.69 17.97 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.542 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.757 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.439 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -157.85 -159.91 9.87 Favored Glycine 0 N--CA 1.442 -0.95 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.556 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 13.9 p90 -140.37 145.05 36.62 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 117.654 0.727 . . . . 0.0 110.563 178.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.426 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 29.2 m -73.25 126.99 31.36 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.562 -0.745 . . . . 0.0 111.036 -179.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 28.7 ttm180 -140.99 138.33 33.66 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.796 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.472 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 18.1 p30 -70.84 140.5 86.36 Favored Pre-proline 0 C--N 1.319 -0.736 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 179.207 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 20.9 Cg_exo -67.57 23.64 0.12 Allowed 'Trans proline' 0 CA--C 1.535 0.539 0 C-N-CA 122.968 2.445 . . . . 0.0 113.14 -179.144 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.468 ' H ' ' C ' ' A' ' 34' ' ' ASN . 12.9 m -91.1 -14.67 30.79 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.175 0.512 . . . . 0.0 109.985 179.035 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.001 0 CA-C-O 118.381 -1.233 . . . . 0.0 111.929 -179.959 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 0.9 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 38.8 m -67.8 73.92 0.18 Allowed 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.344 0.592 . . . . 0.0 111.047 -179.893 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 69.2 m -139.5 65.61 1.43 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.793 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -143.76 110.98 5.78 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 115.134 -0.939 . . . . 0.0 109.6 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 164.56 -151.49 20.62 Favored Glycine 0 N--CA 1.442 -0.912 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 -179.629 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.508 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 67.9 t -112.64 145.45 18.65 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.94 0 CA-C-O 121.029 0.443 . . . . 0.0 110.957 179.719 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.836 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.1 139.33 21.26 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.574 179.91 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.668 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 38.5 t -84.8 137.84 37.97 Favored Pre-proline 0 C--N 1.321 -0.654 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 177.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 30.1 Cg_exo -63.93 -6.79 11.74 Favored 'Trans proline' 0 C--N 1.343 0.26 0 C-N-CA 122.538 2.159 . . . . 0.0 112.24 -179.157 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.3 m-85 -88.53 -21.74 23.97 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.657 -0.701 . . . . 0.0 109.818 179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.668 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.5 mt-10 -78.52 129.97 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.997 -179.932 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.423 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 55.6 ttp -142.07 122.9 8.51 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.033 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.435 ' HG2' ' HA2' ' A' ' 16' ' ' GLY . 84.8 Cg_endo -79.15 144.17 72.28 Favored 'Cis proline' 0 CA--C 1.529 0.244 0 C-N-CA 123.456 -1.477 . . . . 0.0 112.568 -0.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.836 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 23.0 Cg_exo -62.16 133.28 43.02 Favored 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 122.656 2.237 . . . . 0.0 111.322 179.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER 60.99 14.1 5.06 Favored 'General case' 0 N--CA 1.468 0.473 0 C-N-CA 122.671 0.388 . . . . 0.0 111.067 -178.623 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.435 ' HA2' ' HG2' ' A' ' 13' ' ' PRO . . . 54.06 33.75 51.6 Favored Glycine 0 C--N 1.336 0.529 0 CA-C-N 115.948 -0.569 . . . . 0.0 112.769 -179.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.529 HG21 ' HB2' ' A' ' 20' ' ' CYS . 5.7 t -115.25 -40.02 3.52 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.825 0.312 . . . . 0.0 111.793 -179.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 21.4 t 72.83 -42.42 0.53 Allowed 'General case' 0 N--CA 1.469 0.514 0 C-N-CA 123.178 0.591 . . . . 0.0 111.268 -179.166 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -64.38 -34.8 79.01 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 121.12 0.486 . . . . 0.0 111.071 179.945 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.789 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 59.2 m -98.0 151.02 20.75 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.894 179.619 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 16.9 ptp180 -99.42 153.05 19.3 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.364 0.602 . . . . 0.0 111.707 -178.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.576 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 20.7 t -99.55 126.53 45.54 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 108.62 -0.882 . . . . 0.0 108.62 179.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 21.6 mm -89.14 111.98 48.33 Favored Pre-proline 0 C--N 1.32 -0.697 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.59 64.04 6.52 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 123.366 2.71 . . . . 0.0 112.664 -179.43 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.546 HG22 ' HA2' ' A' ' 30' ' ' GLY . 14.8 m -66.12 -31.67 54.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.35 179.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -110.47 168.0 12.84 Favored Glycine 0 N--CA 1.447 -0.62 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 178.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 87.7 mt -64.02 -47.03 81.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 117.175 0.488 . . . . 0.0 111.892 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 30.7 m -123.29 20.38 4.75 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.375 0.607 . . . . 0.0 110.805 -179.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 12.5 tt -150.17 146.93 16.44 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-N 115.532 -0.758 . . . . 0.0 110.598 179.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.546 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -151.73 -160.14 9.33 Favored Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.446 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 21.3 p90 -140.27 142.58 35.72 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 117.582 0.691 . . . . 0.0 110.392 179.172 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 57.8 m -68.4 130.86 44.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.093 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 6.7 tpm_? -138.79 116.57 11.5 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-O 121.264 0.554 . . . . 0.0 111.194 -178.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 14.7 p30 -70.55 136.3 86.02 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 115.726 -0.67 . . . . 0.0 109.446 178.803 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.789 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 67.6 Cg_endo -81.14 37.8 0.71 Allowed 'Trans proline' 0 N--CA 1.457 -0.666 0 C-N-CA 122.704 2.27 . . . . 0.0 111.794 -179.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.8 m -88.36 -27.05 21.88 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.602 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.809 -0.995 . . . . 0.0 111.852 179.738 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 0.98 0 CA-C-O 120.733 0.301 . . . . 0.0 110.303 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 36.1 m -62.07 124.46 20.89 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.142 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 74.8 m -83.08 59.12 4.77 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.715 0.769 . . . . 0.0 110.91 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 52.8 t30 -164.58 130.82 2.92 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 114.319 -1.309 . . . . 0.0 108.623 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.408 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 139.57 -139.76 10.26 Favored Glycine 0 N--CA 1.442 -0.92 0 N-CA-C 110.796 -0.922 . . . . 0.0 110.796 -178.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.546 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -120.71 145.26 27.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 117.229 0.514 . . . . 0.0 111.248 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 10.2 p -147.49 141.55 26.0 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.727 -0.669 . . . . 0.0 109.619 179.437 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.432 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 32.8 m -96.96 142.69 24.91 Favored Pre-proline 0 N--CA 1.436 -1.144 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 27.4 Cg_exo -64.13 -3.54 6.25 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.163 2.575 . . . . 0.0 112.765 -179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -87.27 -29.78 21.39 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.266 -179.99 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.741 ' HB2' ' HA ' ' A' ' 14' ' ' PRO . 47.8 mt-10 -62.56 135.68 57.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.614 179.928 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.4 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 67.1 mtt -141.38 104.77 5.99 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.145 179.346 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.4 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 74.2 Cg_endo -76.18 144.92 80.94 Favored 'Cis proline' 0 CA--C 1.532 0.378 0 C-N-CA 123.39 -1.504 . . . . 0.0 112.325 -0.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.762 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 18.0 Cg_endo -60.5 140.14 89.84 Favored 'Trans proline' 0 C--O 1.233 0.242 0 C-N-CA 122.804 2.336 . . . . 0.0 112.464 -179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 9.1 t 68.21 7.73 6.09 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.77 -179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 71.4 41.33 58.77 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 116.034 -0.53 . . . . 0.0 113.155 179.207 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.3 t -169.8 146.21 3.16 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.05 0.452 . . . . 0.0 110.786 179.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 15.0 m -100.98 -13.96 18.06 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.525 179.505 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -73.19 -28.52 62.25 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.578 -0.737 . . . . 0.0 110.983 -179.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.535 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 88.2 m -117.88 150.65 38.85 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.924 -179.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.3 ptp180 -99.28 157.67 16.23 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.814 -0.63 . . . . 0.0 111.856 -178.673 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.762 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 44.7 t -104.74 128.1 52.74 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.315 179.148 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 25' ' ' VAL . 35.5 mm -94.95 107.24 30.11 Favored Pre-proline 0 C--N 1.322 -0.604 0 N-CA-C 109.919 -0.4 . . . . 0.0 109.919 -179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' O ' ' A' ' 22' ' ' CYS . 7.9 Cg_exo -73.77 67.6 4.76 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 123.546 2.831 . . . . 0.0 114.02 -178.407 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 23' ' ' ILE . 17.0 m -81.57 32.53 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-O 121.587 0.708 . . . . 0.0 110.575 178.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.403 ' H ' ' C ' ' A' ' 24' ' ' PRO . . . -166.64 163.77 37.23 Favored Glycine 0 N--CA 1.44 -1.055 0 N-CA-C 110.449 -1.06 . . . . 0.0 110.449 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 82.8 mt -60.48 -46.15 91.16 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-O 120.563 0.22 . . . . 0.0 111.59 -179.107 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.5 m -133.51 25.1 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.17 0.51 . . . . 0.0 110.64 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.444 HG12 ' N ' ' A' ' 30' ' ' GLY . 11.1 tt -151.31 157.37 5.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 CA-C-N 115.862 -0.608 . . . . 0.0 110.384 -179.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.444 ' N ' HG12 ' A' ' 29' ' ' ILE . . . -159.63 -156.42 8.1 Favored Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 110.8 -0.92 . . . . 0.0 110.8 179.465 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.546 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 7.0 p90 -140.12 145.2 37.27 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 117.498 0.649 . . . . 0.0 111.026 179.227 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 59.1 m -67.26 133.17 49.2 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.613 -0.721 . . . . 0.0 110.226 -179.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HB3' HG12 ' A' ' 23' ' ' ILE . 17.9 tpp180 -140.56 127.25 20.35 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.157 0.503 . . . . 0.0 111.227 -179.032 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 6.8 p30 -84.56 136.39 39.75 Favored Pre-proline 0 C--N 1.319 -0.732 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.496 178.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.535 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 22.2 Cg_exo -65.31 -35.25 41.29 Favored 'Trans proline' 0 N--CA 1.462 -0.363 0 C-N-CA 122.495 2.13 . . . . 0.0 111.495 179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 21.1 m -151.85 49.01 0.79 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.077 0.465 . . . . 0.0 110.501 -179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.076 0 CA-C-O 118.81 -0.995 . . . . 0.0 112.628 -179.569 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.476 0.873 0 CA-C-O 120.823 0.344 . . . . 0.0 110.753 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.5 t -78.88 104.06 9.25 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 178.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 23.5 m -141.95 126.26 17.59 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.275 -178.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 21.0 t-20 179.69 117.76 0.05 Allowed 'General case' 0 C--N 1.326 -0.446 0 O-C-N 123.56 0.537 . . . . 0.0 110.054 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 162.81 -156.62 28.4 Favored Glycine 0 CA--C 1.506 -0.521 0 N-CA-C 111.296 -0.722 . . . . 0.0 111.296 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.534 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 56.0 t -115.91 144.72 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.729 0 CA-C-O 120.659 0.266 . . . . 0.0 110.58 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.714 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 8.5 p -144.09 134.19 24.21 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.159 0.504 . . . . 0.0 111.941 -179.219 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.445 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 4.6 m -88.5 134.31 34.55 Favored Pre-proline 0 N--CA 1.432 -1.355 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 177.779 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 30.7 Cg_exo -64.48 -4.24 7.86 Favored 'Trans proline' 0 N--CA 1.476 0.48 0 C-N-CA 123.273 2.649 . . . . 0.0 113.543 -178.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -86.77 -38.97 16.38 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 120.946 0.403 . . . . 0.0 110.197 -179.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -76.62 126.07 30.34 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.942 179.354 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 91.5 mtp -140.45 130.48 13.54 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.289 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.418 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 57.0 Cg_endo -70.92 139.57 58.81 Favored 'Cis proline' 0 C--O 1.235 0.339 0 C-N-CA 123.176 -1.593 . . . . 0.0 112.231 -0.232 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.487 ' CB ' ' HB2' ' A' ' 22' ' ' CYS . 51.8 Cg_exo -54.4 134.21 60.16 Favored 'Trans proline' 0 C--O 1.233 0.25 0 C-N-CA 122.984 2.456 . . . . 0.0 112.465 -179.421 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.714 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 80.2 m 62.07 22.29 13.0 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.071 -179.086 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 57.62 47.06 91.07 Favored Glycine 0 N--CA 1.449 -0.478 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.059 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.407 ' O ' ' HB2' ' A' ' 13' ' ' PRO . 15.1 t -162.09 142.85 10.45 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.248 0.547 . . . . 0.0 111.153 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 9.9 m -95.12 -13.76 24.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.84 179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -76.66 -36.29 57.43 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.549 -0.751 . . . . 0.0 112.042 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 23.1 m -98.86 140.28 33.26 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.804 -179.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 8.6 ptp180 -99.9 152.08 20.57 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 120.819 0.342 . . . . 0.0 110.533 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.487 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 32.8 t -98.49 126.77 44.16 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.525 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.539 HG22 HG13 ' A' ' 25' ' ' VAL . 26.5 mm -96.32 108.69 43.36 Favored Pre-proline 0 C--N 1.322 -0.616 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 178.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 10.2 Cg_exo -71.91 67.4 3.19 Favored 'Trans proline' 0 CA--C 1.529 0.274 0 C-N-CA 123.307 2.671 . . . . 0.0 114.089 -177.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.539 HG13 HG22 ' A' ' 23' ' ' ILE . 17.4 m -85.72 36.68 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 121.513 0.673 . . . . 0.0 110.482 178.462 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.29 161.79 31.92 Favored Glycine 0 N--CA 1.444 -0.814 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 -179.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 71.2 mt -64.12 -43.68 94.55 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 117.288 0.544 . . . . 0.0 111.211 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 33.8 m -130.72 21.99 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-O 120.874 0.368 . . . . 0.0 111.211 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 15.0 tt -151.84 148.42 14.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 116.307 -0.406 . . . . 0.0 111.198 179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.441 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -152.78 -160.09 9.43 Favored Glycine 0 N--CA 1.442 -0.954 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 16.5 p90 -140.21 140.0 35.75 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 117.703 0.752 . . . . 0.0 110.678 179.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.459 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 4.8 m -80.44 130.38 35.12 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 121.129 0.49 . . . . 0.0 110.979 -179.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 58.2 ttp180 -140.22 146.51 38.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.739 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 3.1 p30 -74.21 126.17 89.34 Favored Pre-proline 0 C--N 1.324 -0.525 0 CA-C-O 121.14 0.495 . . . . 0.0 111.38 -179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -62.26 -36.08 70.24 Favored 'Trans proline' 0 N--CA 1.464 -0.24 0 C-N-CA 122.954 2.436 . . . . 0.0 111.76 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.7 p -92.39 -69.61 0.74 Allowed 'General case' 0 N--CA 1.449 -0.524 0 CA-C-O 121.357 0.598 . . . . 0.0 110.596 179.843 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 1.027 0 CA-C-N 115.239 -0.891 . . . . 0.0 111.425 179.798 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.034 0 CA-C-O 120.91 0.386 . . . . 0.0 110.608 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 10.1 t -158.84 58.36 0.43 Allowed 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.074 -0.713 . . . . 0.0 109.074 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.464 ' HB2' ' HB3' ' A' ' 34' ' ' ASN . 93.6 m -73.62 91.94 1.9 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.583 -0.735 . . . . 0.0 111.227 -179.52 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 9.0 p30 -159.92 124.1 3.77 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.428 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . 0.417 ' O ' ' HB2' ' A' ' 31' ' ' TYR . . . 161.26 -145.07 10.46 Favored Glycine 0 N--CA 1.445 -0.714 0 N-CA-C 110.926 -0.869 . . . . 0.0 110.926 -179.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.436 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 84.7 t -115.15 147.41 18.57 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-N 117.167 0.484 . . . . 0.0 111.201 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.452 ' SG ' ' N ' ' A' ' 8' ' ' SER . 0.5 OUTLIER -139.99 179.13 6.79 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 179.365 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.452 ' N ' ' SG ' ' A' ' 7' ' ' CYS . 29.2 t -129.17 132.6 24.42 Favored Pre-proline 0 C--N 1.322 -0.622 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 177.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 49.1 Cg_exo -58.87 -19.48 47.42 Favored 'Trans proline' 0 C--N 1.344 0.326 0 C-N-CA 123.403 2.735 . . . . 0.0 113.3 -178.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.417 ' CE1' HG12 ' A' ' 28' ' ' VAL . 3.9 m-85 -88.36 -29.96 19.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.158 0.504 . . . . 0.0 109.956 -179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 6.1 mm-40 -71.67 131.41 43.12 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.503 -0.772 . . . . 0.0 110.904 179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 47.4 ttm -143.19 112.87 5.66 Favored Pre-proline 0 C--N 1.32 -0.706 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.175 178.708 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 20.5 Cg_exo -66.08 144.67 66.74 Favored 'Cis proline' 0 C--N 1.345 0.364 0 C-N-CA 123.726 -1.364 . . . . 0.0 112.193 -0.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 4.0 Cg_endo -50.98 -80.99 0.02 OUTLIER 'Trans proline' 0 CA--C 1.533 0.472 0 C-N-CA 123.272 2.648 . . . . 0.0 113.237 -178.341 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.463 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . 0.5 OUTLIER -66.85 -50.65 61.87 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.693 0.282 . . . . 0.0 111.231 179.862 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 176.57 -48.98 0.11 Allowed Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 120.627 -0.796 . . . . 0.0 112.082 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 10.6 t -91.64 138.54 31.49 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 121.097 0.475 . . . . 0.0 110.742 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 8.4 t -79.37 -19.02 51.18 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.976 -0.557 . . . . 0.0 109.605 179.583 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.53 -25.9 67.65 Favored 'General case' 0 C--O 1.232 0.182 0 CA-C-N 115.584 -0.735 . . . . 0.0 111.023 179.774 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 91.3 m -107.25 150.92 26.12 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.491 179.744 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 3.7 ptp180 -100.22 -172.61 2.25 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.789 -0.448 . . . . 0.0 109.789 179.862 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 41.7 t -144.27 142.02 30.19 Favored 'General case' 0 N--CA 1.438 -1.025 0 CA-C-O 121.025 0.44 . . . . 0.0 110.51 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.499 HG22 HG13 ' A' ' 25' ' ' VAL . 12.7 mm -93.64 112.49 56.98 Favored Pre-proline 0 C--N 1.317 -0.827 0 CA-C-N 115.476 -0.784 . . . . 0.0 109.779 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.439 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 3.0 Cg_exo -75.35 63.28 6.27 Favored 'Trans proline' 0 C--O 1.23 0.124 0 C-N-CA 123.39 2.727 . . . . 0.0 113.526 -178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.499 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -80.92 36.61 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-O 121.129 0.49 . . . . 0.0 110.865 178.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -174.72 155.88 21.79 Favored Glycine 0 N--CA 1.445 -0.71 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.0 mt -59.17 -45.63 90.51 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 116.642 0.221 . . . . 0.0 111.565 -179.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.417 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.0 m -131.41 22.28 1.7 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-O 121.055 0.455 . . . . 0.0 110.986 179.897 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.71 141.64 15.44 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.856 179.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -148.24 -169.38 15.17 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 179.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.436 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.8 p90 -127.68 134.83 49.6 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 118.225 1.012 . . . . 0.0 110.959 179.038 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.463 ' HB2' ' HB3' ' A' ' 15' ' ' CYS . 29.8 t -64.78 131.25 46.3 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.332 -179.151 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 2.1 tpm_? -141.53 129.91 22.44 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.708 -179.373 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.482 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 20.7 p30 -72.06 139.24 82.24 Favored Pre-proline 0 C--N 1.323 -0.585 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 179.195 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 3.0 Cg_exo -78.05 -0.33 10.57 Favored 'Trans proline' 0 CA--C 1.529 0.252 0 C-N-CA 122.993 2.462 . . . . 0.0 113.056 -178.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 2.8 p -88.61 -37.48 15.6 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.949 0.404 . . . . 0.0 111.854 -179.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.948 0 CA-C-O 118.626 -1.097 . . . . 0.0 112.271 -179.667 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.015 0 CA-C-O 120.925 0.393 . . . . 0.0 110.744 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 13.7 p -77.23 57.87 1.52 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.577 0.703 . . . . 0.0 110.679 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.758 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 30.8 t -69.08 123.11 20.19 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.149 -0.932 . . . . 0.0 111.516 -178.902 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.47 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 53.2 t30 -159.08 134.07 8.22 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.313 179.56 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 152.27 -144.02 11.05 Favored Glycine 0 C--O 1.222 -0.608 0 N-CA-C 110.824 -0.91 . . . . 0.0 110.824 -179.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.599 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 45.9 t -119.52 141.93 37.27 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 117.196 0.498 . . . . 0.0 109.672 178.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 15' ' ' CYS . 12.3 p -147.51 141.48 25.92 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.728 0.299 . . . . 0.0 111.444 -179.157 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.472 ' HB2' ' CG ' ' A' ' 11' ' ' GLU . 13.5 m -86.82 129.87 50.81 Favored Pre-proline 0 N--CA 1.436 -1.171 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 31.8 Cg_exo -61.18 -23.12 76.57 Favored 'Trans proline' 0 C--O 1.235 0.325 0 C-N-CA 123.31 2.674 . . . . 0.0 113.251 -178.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.524 ' CE1' HG12 ' A' ' 28' ' ' VAL . 4.1 m-85 -87.96 -19.13 27.65 Favored 'General case' 0 C--N 1.324 -0.522 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.675 -179.236 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.472 ' CG ' ' HB2' ' A' ' 8' ' ' SER . 6.2 mm-40 -78.92 132.89 36.91 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.436 179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 51.7 ttp -140.75 128.85 12.51 Favored Pre-proline 0 C--N 1.322 -0.626 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.67 -179.523 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 87.7 Cg_endo -77.81 137.79 48.83 Favored 'Cis proline' 0 C--O 1.234 0.282 0 C-N-CA 123.29 -1.546 . . . . 0.0 111.775 -0.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.533 ' HB2' ' HB2' ' A' ' 22' ' ' CYS . 25.1 Cg_endo -66.04 140.75 61.22 Favored 'Trans proline' 0 N--CA 1.457 -0.665 0 C-N-CA 121.905 1.736 . . . . 0.0 111.822 -179.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 13.0 m 65.22 11.65 7.4 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 115.32 -0.855 . . . . 0.0 111.876 -179.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 53.62 42.79 67.71 Favored Glycine 0 C--N 1.334 0.469 0 C-N-CA 121.236 -0.507 . . . . 0.0 112.393 179.669 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.487 HG22 ' HB2' ' A' ' 15' ' ' CYS . 9.5 t -143.84 -39.77 0.3 Allowed 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 120.907 -0.317 . . . . 0.0 111.57 -179.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 22.8 t 72.03 -39.14 0.44 Allowed 'General case' 0 N--CA 1.472 0.668 0 C-N-CA 122.929 0.491 . . . . 0.0 111.613 -179.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . 0.408 ' H ' ' C ' ' A' ' 17' ' ' THR . . . -62.67 -28.91 70.25 Favored 'General case' 0 C--N 1.33 -0.266 0 C-N-CA 122.675 0.39 . . . . 0.0 111.369 -179.94 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.6 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 0.5 OUTLIER -98.08 156.94 16.42 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 109.717 -0.475 . . . . 0.0 109.717 179.974 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 38.0 ptt180 -99.76 133.67 43.77 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.345 0.593 . . . . 0.0 111.596 -179.031 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.533 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 47.4 t -89.96 131.4 35.88 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.406 179.227 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.464 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 23.4 mm -98.7 109.15 52.15 Favored Pre-proline 0 C--N 1.32 -0.678 0 C-N-CA 121.193 -0.203 . . . . 0.0 110.933 -179.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -75.45 65.68 6.43 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.511 2.808 . . . . 0.0 113.077 -179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.499 HG22 ' HA2' ' A' ' 30' ' ' GLY . 10.3 m -69.77 -33.19 55.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.46 0 CA-C-O 120.929 0.395 . . . . 0.0 110.722 179.442 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -98.78 -179.85 31.78 Favored Glycine 0 N--CA 1.448 -0.515 0 N-CA-C 111.376 -0.689 . . . . 0.0 111.376 178.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.4 mt -66.22 -52.1 51.15 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 120.895 0.378 . . . . 0.0 111.196 -179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.524 HG12 ' CE1' ' A' ' 10' ' ' PHE . 35.1 m -132.06 28.57 1.27 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 121.934 0.873 . . . . 0.0 109.536 179.521 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.448 HD11 HG11 ' A' ' 6' ' ' VAL . 19.5 tt -150.71 155.41 7.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-N 114.603 -1.181 . . . . 0.0 109.269 179.138 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.499 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -161.32 -153.0 6.85 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.626 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.599 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 20.6 p90 -140.42 143.44 35.62 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 117.534 0.667 . . . . 0.0 111.258 179.439 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 79.4 m -74.05 131.39 41.31 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.259 -0.882 . . . . 0.0 111.249 -179.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 20.7 ttm180 -142.19 135.39 28.89 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-O 121.019 0.438 . . . . 0.0 111.243 179.579 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 15.6 p30 -71.7 140.39 84.02 Favored Pre-proline 0 C--N 1.323 -0.552 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 179.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.6 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 31.5 Cg_exo -61.99 -12.73 27.46 Favored 'Trans proline' 0 CA--C 1.529 0.26 0 C-N-CA 123.093 2.529 . . . . 0.0 113.206 -178.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 11.5 m -89.48 13.21 14.35 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.037 0.446 . . . . 0.0 111.148 -179.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.815 0 CA-C-O 118.81 -0.994 . . . . 0.0 111.811 -179.784 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.952 0 CA-C-O 120.672 0.272 . . . . 0.0 110.41 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 7.9 t -63.05 145.14 56.09 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.108 179.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 99.0 m -77.17 68.97 3.39 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.426 0.631 . . . . 0.0 111.883 -179.345 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 67.0 m-20 -140.9 117.93 11.19 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.269 178.674 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 159.68 170.99 24.94 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 110.983 -0.847 . . . . 0.0 110.983 -178.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.555 HG13 ' O ' ' A' ' 30' ' ' GLY . 67.5 t -89.58 146.14 6.54 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.14 0 CA-C-O 121.137 0.494 . . . . 0.0 111.244 -179.602 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.494 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . 9.8 p -146.76 142.03 27.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.813 -0.631 . . . . 0.0 110.926 -179.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.429 ' HB3' ' CG ' ' A' ' 11' ' ' GLU . 14.0 t -83.7 134.89 43.81 Favored Pre-proline 0 C--N 1.315 -0.899 0 N-CA-C 108.1 -1.074 . . . . 0.0 108.1 177.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 29.2 Cg_exo -63.57 -16.37 54.24 Favored 'Trans proline' 0 C--O 1.232 0.208 0 C-N-CA 122.476 2.117 . . . . 0.0 111.937 -179.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 4.1 m-85 -88.92 -33.14 17.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.061 179.976 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.429 ' CG ' ' HB3' ' A' ' 8' ' ' SER . 6.0 mm-40 -67.02 128.34 35.97 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.915 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . . . . . . . . . 69.3 mtm -140.42 128.76 12.85 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.16 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.416 ' HA ' ' HD3' ' A' ' 14' ' ' PRO . 92.0 Cg_endo -80.72 141.09 53.47 Favored 'Cis proline' 0 N--CA 1.463 -0.305 0 C-N-CA 123.336 -1.527 . . . . 0.0 112.1 -0.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.416 ' HD3' ' HA ' ' A' ' 13' ' ' PRO . 15.0 Cg_exo -65.68 126.74 16.6 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.319 2.013 . . . . 0.0 111.365 179.687 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.409 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 61.6 m 59.24 23.28 11.63 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-N 115.782 -0.644 . . . . 0.0 111.92 -179.367 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 61.64 50.61 64.49 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 121.158 -0.544 . . . . 0.0 113.28 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 14.9 t -167.3 147.31 5.33 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 121.124 0.487 . . . . 0.0 111.278 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 68.7 m -114.4 -0.49 13.78 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 178.525 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -80.49 -41.68 23.87 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.503 179.257 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.675 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 68.9 m -99.1 145.85 26.72 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.221 -0.9 . . . . 0.0 109.416 178.905 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 13.4 ptp180 -99.44 149.93 22.69 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.241 0.543 . . . . 0.0 112.088 -178.328 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.413 ' O ' ' HD3' ' A' ' 24' ' ' PRO . 41.9 t -93.45 124.42 37.43 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 178.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.428 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 15.8 mm -89.95 109.03 29.87 Favored Pre-proline 0 C--N 1.321 -0.672 0 N-CA-C 110.148 -0.315 . . . . 0.0 110.148 -179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 5.9 Cg_exo -74.37 64.67 5.45 Favored 'Trans proline' 0 C--O 1.233 0.241 0 C-N-CA 123.425 2.75 . . . . 0.0 112.582 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.582 HG22 ' HA2' ' A' ' 30' ' ' GLY . 6.3 m -66.02 -41.85 90.5 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.526 0 CA-C-N 115.954 -0.566 . . . . 0.0 111.243 -179.732 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -92.44 -171.77 41.21 Favored Glycine 0 N--CA 1.447 -0.567 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.503 178.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 83.8 mt -74.89 -48.19 26.07 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.101 0.476 . . . . 0.0 110.609 179.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.8 m -131.66 28.68 1.33 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.594 0.711 . . . . 0.0 109.916 179.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 8.3 tt -150.16 149.07 14.82 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.814 179.622 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.582 ' HA2' HG22 ' A' ' 25' ' ' VAL . . . -157.05 -162.95 11.92 Favored Glycine 0 N--CA 1.438 -1.217 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.466 ' HE2' HG11 ' A' ' 25' ' ' VAL . 26.3 p90 -140.94 137.67 33.27 Favored 'General case' 0 C--N 1.313 -0.985 0 CA-C-N 117.314 0.557 . . . . 0.0 110.073 179.38 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.494 ' SG ' ' HB3' ' A' ' 7' ' ' CYS . 56.0 m -74.69 129.36 37.56 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 116.018 -0.537 . . . . 0.0 111.13 -179.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.432 ' HD3' ' O ' ' A' ' 37' ' ' GLY . 35.1 ttm180 -141.11 137.92 33.14 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 121.163 0.506 . . . . 0.0 110.097 178.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.494 ' C ' ' H ' ' A' ' 36' ' ' SER . 16.7 p30 -68.97 144.65 95.94 Favored Pre-proline 0 C--N 1.32 -0.7 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.808 179.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.675 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 16.3 Cg_exo -68.16 30.29 0.14 Allowed 'Trans proline' 0 CA--C 1.535 0.561 0 C-N-CA 123.022 2.481 . . . . 0.0 112.545 -179.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.494 ' H ' ' C ' ' A' ' 34' ' ' ASN . 10.7 t -131.95 34.03 3.88 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 179.176 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 33' ' ' ARG . . . . . . . . 0 C--O 1.252 1.233 0 CA-C-O 118.862 -0.966 . . . . 0.0 111.578 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.014 0 N-CA-C 110.252 -0.277 . . . . 0.0 110.252 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 55.1 m 55.37 45.36 25.57 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-O 121.543 0.687 . . . . 0.0 109.962 -179.197 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . 0.677 ' SG ' ' HB3' ' A' ' 32' ' ' CYS . 40.1 t -65.88 131.91 47.39 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.999 -178.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . 0.473 ' HA ' ' O ' ' A' ' 32' ' ' CYS . 7.5 p-10 -171.64 135.85 0.91 Allowed 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.196 178.92 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 154.08 -156.48 26.85 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 121.011 -0.614 . . . . 0.0 111.655 -179.554 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.554 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 54.8 t -117.08 142.3 31.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 120.829 0.347 . . . . 0.0 111.008 179.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.776 ' SG ' ' HB3' ' A' ' 14' ' ' PRO . 0.0 OUTLIER -150.66 144.97 25.54 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.89 -0.596 . . . . 0.0 110.493 -179.792 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.643 ' HB3' ' HG3' ' A' ' 11' ' ' GLU . 46.1 t -83.45 133.86 46.37 Favored Pre-proline 0 N--CA 1.447 -0.606 0 N-CA-C 106.97 -1.493 . . . . 0.0 106.97 176.766 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 35.8 Cg_exo -62.32 -9.96 17.01 Favored 'Trans proline' 0 N--CA 1.472 0.222 0 C-N-CA 122.815 2.343 . . . . 0.0 112.991 -178.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -87.43 -27.15 22.89 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.164 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.643 ' HG3' ' HB3' ' A' ' 8' ' ' SER . 38.3 mt-10 -72.04 129.07 37.65 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.901 179.815 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.621 ' SD ' ' HD3' ' A' ' 14' ' ' PRO . 16.8 tpt -141.08 124.25 9.89 Favored Pre-proline 0 C--N 1.32 -0.702 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 179.496 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.531 ' HA ' ' SD ' ' A' ' 12' ' ' MET . 76.9 Cg_endo -77.75 143.72 74.71 Favored 'Cis proline' 0 CA--C 1.531 0.359 0 C-N-CA 123.509 -1.454 . . . . 0.0 112.611 0.084 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.776 ' HB3' ' SG ' ' A' ' 7' ' ' CYS . 24.5 Cg_exo -62.41 133.22 41.94 Favored 'Trans proline' 0 C--O 1.238 0.479 0 C-N-CA 122.638 2.226 . . . . 0.0 111.84 179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 65.3 m 59.35 13.19 3.01 Favored 'General case' 0 CA--C 1.535 0.392 0 CA-C-N 115.637 -0.71 . . . . 0.0 112.851 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 55.81 51.96 51.72 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 121.624 -0.322 . . . . 0.0 113.889 178.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . 0.414 ' O ' ' HB2' ' A' ' 18' ' ' SER . 5.9 t -141.89 -31.06 0.56 Allowed 'General case' 0 C--N 1.324 -0.538 0 C-N-CA 120.649 -0.42 . . . . 0.0 112.082 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.414 ' HB2' ' O ' ' A' ' 17' ' ' THR . 73.6 m 70.07 -41.03 0.48 Allowed 'General case' 0 N--CA 1.47 0.561 0 N-CA-C 112.88 0.696 . . . . 0.0 112.88 179.332 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -66.26 -18.67 65.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.311 0.577 . . . . 0.0 111.301 -179.892 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 30.8 t -97.45 175.39 6.25 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.374 -179.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 10.0 ptp180 -131.79 145.79 51.78 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.542 178.447 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.483 ' HB2' ' CB ' ' A' ' 14' ' ' PRO . 12.3 t -105.27 122.55 46.16 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.912 -0.586 . . . . 0.0 110.636 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.481 HG22 HG13 ' A' ' 25' ' ' VAL . 18.4 mm -90.01 114.38 60.62 Favored Pre-proline 0 C--N 1.322 -0.589 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.389 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 3.2 Cg_exo -75.36 65.42 6.37 Favored 'Trans proline' 0 N--CA 1.463 -0.274 0 C-N-CA 123.227 2.618 . . . . 0.0 113.709 -178.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.481 HG13 HG22 ' A' ' 23' ' ' ILE . 15.9 m -82.59 38.1 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.529 0 CA-C-O 121.649 0.737 . . . . 0.0 110.199 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.98 167.68 40.24 Favored Glycine 0 N--CA 1.443 -0.877 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 -179.264 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 85.5 mt -64.93 -47.91 76.0 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 120.712 0.291 . . . . 0.0 110.727 -179.742 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 26.8 m -134.02 25.22 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.127 0.489 . . . . 0.0 110.725 179.531 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.423 HD11 HG11 ' A' ' 6' ' ' VAL . 18.2 tt -150.35 148.29 15.34 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.444 179.362 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.476 ' O ' HG13 ' A' ' 6' ' ' VAL . . . -156.23 -155.92 7.61 Favored Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.554 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 25.5 p90 -140.71 140.95 34.98 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 117.711 0.755 . . . . 0.0 111.179 179.357 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.677 ' HB3' ' SG ' ' A' ' 3' ' ' CYS . 67.3 m -83.04 131.24 35.18 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.185 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 7.8 ptm180 -142.12 141.65 32.7 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 178.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.522 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 13.7 p30 -70.48 135.59 86.31 Favored Pre-proline 0 C--N 1.318 -0.793 0 CA-C-O 121.029 0.442 . . . . 0.0 110.168 -179.465 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.522 ' HD3' ' HA ' ' A' ' 34' ' ' ASN . 17.4 Cg_exo -68.31 1.98 3.13 Favored 'Trans proline' 0 CA--C 1.529 0.257 0 C-N-CA 123.353 2.702 . . . . 0.0 113.817 -178.358 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 19.7 m -88.82 -49.29 6.92 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.125 0.488 . . . . 0.0 111.008 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.103 0 CA-C-O 118.741 -1.033 . . . . 0.0 111.954 179.629 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.951 0 CA-C-O 120.733 0.301 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 27.0 m -79.85 57.36 2.55 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-O 121.169 0.509 . . . . 0.0 111.266 -179.794 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 60.5 m -83.19 130.19 35.07 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.243 -179.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 8.3 p-10 -173.77 148.79 1.5 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.949 -0.569 . . . . 0.0 109.732 179.491 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . 132.19 -150.42 19.62 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.837 -0.696 . . . . 0.0 112.273 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 55.5 t -117.19 143.8 26.62 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.958 ' HB2' ' HB2' ' A' ' 14' ' ' PRO . 32.1 p -136.92 127.09 26.21 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . 0.472 ' HA ' ' HD3' ' A' ' 9' ' ' PRO . 30.2 t -87.94 134.99 34.09 Favored Pre-proline 0 C--N 1.321 -0.637 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 179.372 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . 0.472 ' HD3' ' HA ' ' A' ' 8' ' ' SER . 22.1 Cg_exo -66.77 -19.75 52.92 Favored 'Trans proline' 0 C--N 1.342 0.228 0 C-N-CA 122.87 2.38 . . . . 0.0 112.002 179.953 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.446 ' CE1' HG12 ' A' ' 28' ' ' VAL . 7.0 m-85 -89.14 -37.26 15.19 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.292 -179.72 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 68.3 mm-40 -71.67 136.96 47.5 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.925 -0.58 . . . . 0.0 109.608 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.412 ' HA ' ' HA ' ' A' ' 13' ' ' PRO . 47.3 ttm -141.29 121.13 8.4 Favored Pre-proline 0 C--N 1.318 -0.789 0 C-N-CA 120.881 -0.328 . . . . 0.0 110.767 -179.721 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.412 ' HA ' ' HA ' ' A' ' 12' ' ' MET . 57.5 Cg_endo -73.27 135.34 39.43 Favored 'Cis proline' 0 CA--C 1.533 0.468 0 C-N-CA 123.248 -1.563 . . . . 0.0 112.253 -0.157 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.958 ' HB2' ' HB2' ' A' ' 7' ' ' CYS . 2.9 Cg_endo -49.22 -58.8 1.53 Allowed 'Trans proline' 0 CA--C 1.531 0.372 0 C-N-CA 123.806 3.004 . . . . 0.0 113.641 -178.642 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 47.4 t -84.89 16.65 3.23 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.122 0.487 . . . . 0.0 111.041 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 63.18 29.74 75.38 Favored Glycine 0 N--CA 1.452 -0.25 0 C-N-CA 121.053 -0.594 . . . . 0.0 112.581 179.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 11.4 t -172.05 140.84 1.25 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-O 120.926 0.393 . . . . 0.0 110.318 179.852 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 32.0 t -80.18 -21.46 42.99 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.318 -179.79 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -65.18 -35.12 80.1 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.938 -0.574 . . . . 0.0 111.494 -179.465 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 80.8 m -98.27 144.75 27.36 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.175 -179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 5.4 ptp180 -98.94 153.22 18.99 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.021 0.438 . . . . 0.0 110.539 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . . . . . . . . . 44.1 t -100.17 135.25 41.89 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.915 -0.584 . . . . 0.0 111.085 -179.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.449 HG22 HG13 ' A' ' 25' ' ' VAL . 25.8 mm -107.95 101.89 43.1 Favored Pre-proline 0 C--N 1.326 -0.456 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 178.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -73.12 69.08 3.98 Favored 'Trans proline' 0 CA--C 1.53 0.28 0 C-N-CA 123.497 2.798 . . . . 0.0 113.407 -178.558 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.449 HG13 HG22 ' A' ' 23' ' ' ILE . 3.5 m -73.13 -37.8 53.59 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-O 120.932 0.396 . . . . 0.0 110.825 179.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -90.29 -165.63 40.67 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.643 -0.583 . . . . 0.0 111.643 178.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 88.0 mt -89.84 -48.8 7.0 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.266 0.555 . . . . 0.0 110.009 179.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.446 HG12 ' CE1' ' A' ' 10' ' ' PHE . 19.1 m -123.39 21.62 4.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.791 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 13.9 tt -151.95 152.65 10.63 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.51 179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -153.44 -170.97 20.17 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 179.242 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.537 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 19.8 p90 -127.2 146.44 50.41 Favored 'General case' 0 C--N 1.315 -0.925 0 CA-C-N 118.052 0.926 . . . . 0.0 110.847 179.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 48.4 t -77.12 130.62 37.59 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.819 -179.063 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . . . . . . . . . 21.4 ttm180 -141.34 145.13 35.04 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.633 179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . . . . . . . . . 17.1 p30 -73.06 139.3 79.43 Favored Pre-proline 0 N--CA 1.444 -0.748 0 CA-C-O 121.252 0.549 . . . . 0.0 109.861 179.725 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -62.68 -0.61 2.07 Favored 'Trans proline' 0 CA--C 1.534 0.491 0 C-N-CA 123.786 2.99 . . . . 0.0 114.067 -178.165 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 10.8 t -88.56 -36.85 16.13 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 121.347 0.594 . . . . 0.0 109.916 179.365 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.968 0 CA-C-O 118.843 -0.976 . . . . 0.0 112.295 179.754 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.971 0 CA-C-O 120.69 0.281 . . . . 0.0 110.511 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' SER . . . . . . . . . . . . . 69.0 m -74.96 67.0 1.63 Allowed 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.155 0.502 . . . . 0.0 110.7 179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' CYS . . . . . . . . . . . . . 72.2 m -65.63 120.45 12.96 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.53 -0.759 . . . . 0.0 111.866 -179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -175.53 38.96 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.144 179.935 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLY . . . . . . . . . . . . . . . -124.51 -151.28 8.07 Favored Glycine 0 N--CA 1.447 -0.605 0 C-N-CA 120.472 -0.87 . . . . 0.0 111.961 -179.841 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.58 ' HA ' ' HA ' ' A' ' 31' ' ' TYR . 50.9 t -102.63 147.33 9.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.733 0 CA-C-O 120.843 0.354 . . . . 0.0 110.627 -179.968 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 30.0 p -147.76 140.25 24.55 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.253 -0.431 . . . . 0.0 110.628 179.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' SER . . . . . . . . . . . . . 5.1 m -90.74 133.01 33.26 Favored Pre-proline 0 N--CA 1.434 -1.24 0 N-CA-C 108.554 -0.906 . . . . 0.0 108.554 178.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' PRO . . . . . . . . . . . . . 31.6 Cg_exo -61.7 -20.02 67.36 Favored 'Trans proline' 0 C--N 1.344 0.294 0 C-N-CA 122.889 2.393 . . . . 0.0 112.788 -179.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -87.48 -30.64 20.49 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.237 -179.532 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 61.3 mm-40 -73.5 125.64 28.41 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.525 179.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' MET . . . . . 0.506 ' HA ' ' C ' ' A' ' 13' ' ' PRO . 83.4 mtp -140.04 135.49 16.42 Favored Pre-proline 0 C--N 1.326 -0.444 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.603 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.506 ' C ' ' HA ' ' A' ' 12' ' ' MET . 41.8 Cg_endo -67.06 137.42 36.25 Favored 'Cis proline' 0 C--N 1.345 0.362 0 C-N-CA 123.325 -1.531 . . . . 0.0 112.3 -0.2 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' PRO . . . . . 0.773 ' HB3' ' HB2' ' A' ' 22' ' ' CYS . 41.1 Cg_exo -56.42 129.92 37.3 Favored 'Trans proline' 0 N--CA 1.465 -0.197 0 C-N-CA 122.932 2.421 . . . . 0.0 113.107 -179.018 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.538 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . 5.5 t 62.06 27.9 16.86 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.427 179.748 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . 60.68 39.75 97.06 Favored Glycine 0 N--CA 1.449 -0.496 0 CA-C-N 115.531 -0.759 . . . . 0.0 112.985 179.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' THR . . . . . . . . . . . . . 15.0 t -166.88 142.65 4.35 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.397 0.618 . . . . 0.0 110.829 179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . . . . . . . . . 27.6 p -95.0 -13.81 24.91 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.292 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ALA . . . . . . . . . . . . . . . -75.55 -33.39 60.66 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.648 -0.706 . . . . 0.0 112.203 -179.074 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.562 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 55.3 m -97.92 152.99 18.65 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 120.916 0.389 . . . . 0.0 111.105 -178.897 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.1 ptp180 -99.89 145.87 27.29 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.955 179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' CYS . . . . . 0.773 ' HB2' ' HB3' ' A' ' 14' ' ' PRO . 35.6 t -97.57 130.6 44.6 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.938 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.547 ' O ' ' HA3' ' A' ' 30' ' ' GLY . 22.0 mm -103.41 108.38 58.96 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.731 -179.415 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 23' ' ' ILE . 2.9 Cg_exo -75.62 65.76 6.58 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 123.51 2.807 . . . . 0.0 112.975 -179.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.547 HG13 HG22 ' A' ' 23' ' ' ILE . 4.1 m -70.94 -40.88 76.89 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-O 121.014 0.435 . . . . 0.0 110.204 179.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -84.99 -167.71 43.62 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.244 -0.743 . . . . 0.0 111.244 177.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' LEU . . . . . . . . . . . . . 95.4 mt -76.03 -54.51 6.75 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.922 0.391 . . . . 0.0 110.582 179.632 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.8 m -131.53 29.11 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 CA-C-O 121.988 0.899 . . . . 0.0 108.993 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.439 HD11 HG11 ' A' ' 6' ' ' VAL . 15.4 tt -150.43 154.15 9.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-N 114.292 -1.322 . . . . 0.0 109.022 179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.547 ' HA3' ' O ' ' A' ' 23' ' ' ILE . . . -161.87 -147.15 4.89 Favored Glycine 0 N--CA 1.44 -1.096 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.356 -179.89 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' TYR . . . . . 0.58 ' HA ' ' HA ' ' A' ' 6' ' ' VAL . 39.9 p90 -140.28 135.61 32.44 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 117.081 0.44 . . . . 0.0 110.219 179.189 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 15' ' ' CYS . 4.4 p -87.31 124.23 33.14 Favored 'General case' 0 C--N 1.321 -0.647 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.77 179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ARG . . . . . 0.491 ' HD2' ' HE1' ' A' ' 31' ' ' TYR . 16.4 ptm180 -128.02 149.24 50.45 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.812 -0.631 . . . . 0.0 109.905 -179.322 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASN . . . . . 0.428 ' HA ' ' HD3' ' A' ' 35' ' ' PRO . 3.2 m-20 -75.04 135.33 73.75 Favored Pre-proline 0 C--N 1.318 -0.766 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 178.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' PRO . . . . . 0.562 ' HD3' ' HA ' ' A' ' 20' ' ' CYS . 7.0 Cg_exo -73.23 41.9 0.61 Allowed 'Trans proline' 0 CA--C 1.53 0.317 0 C-N-CA 123.081 2.521 . . . . 0.0 112.332 -179.895 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 23.6 p -150.79 27.72 0.71 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.01 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.244 0.771 0 CA-C-O 118.513 -1.16 . . . . 0.0 112.215 179.933 . . . . . . . . 0 0 . 1 stop_ save_